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ABBREVIATIONS 
 
A   Adenine 
Ac2O   Acetic anhydride  
ACN   Acetonitrile 
Aeg    N-(2-aminoethyl) glycine 
AMS   Amino methyl styrene resin 
Bhoc    Benzhydryloxycarbonyl 
Boc    tert-Butyloxycarbonyl 
C    Cytosine 
Cbz   Benzyloxycarbonyl 
CD   Circular dichroism 
CPG   Controlled pore glasses support 
DABA   2,4-diaminobutyric acid 
DCM   Dichloromethane 
DIC   Diiso-propyl carbodiimide 
DMAP  4-(Dimethylamino) pyridine 
DIPEA  Diisopropylethylamine 
DMF   N,N-dimethylformamide 
DMSO  Dimethyl sulfoxide 
Fmoc   9-fluorenylmethoxycarbonyl 
G   Guanine 
HATU   O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate 
HOBt   N-hydroxybenzotriazole 
LC/MS  Liquid chromatography/mass spectroscopy 
LNA   Locked nucleic acid 
MALDI-TOF MS Matrix-assisted laser desorption/ionization time of flight mass spectroscopy 
NMP   1-Methyl-2-pyrrolidinone 
NMR   Nuclear magnetic resonance 
PEG-PS  polyethylene glycol-polystyrene solid support 
PNA    Peptide (polyamide) nucleic acid 
PyBop   benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate 
RP-HPLC  Reverse phase-high performance liquid chromatography 
T    Thymine 
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TCH2COOH   Thymin-1-yl acetic acid 
TFA   Trifluoroacetic acid 
TMP   2,4,6, trimethylpiridine  
TOF-SIMS  Time-of-flight secondary ion mass spectrometry 
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INTRODUCTION 
 
 
The base pairing of nucleic acids is one of the fundamental processes in biological systems, it 
guarantees the storage,  transfer and expression of genetic information in living systems. 
Self-recognition by nucleic acid is based  on the Watson-Crick1 hydrogen bonds between  the 
complementary nucleobases A-T and G-C (Figure 1). 
 
 
 
Figure 1 Watson-Crick hydrogen bonding. 
 
This simple four base recognition has inspired chemists to develop self organizing systems based on 
DNA for therapeutic applications,2 in the form of antisense and antigene oligonucleotides, as well 
as for diagnostic purposes, or for the development of new nanomaterials. 
 
DNA as therapeutic agents 
 
Different cellular processes could be inhibited depending on the site at which the oligonucleotide 
hybridizes to the target nucleic acid. The oligonucleotides that interact with single stranded RNA 
are called “antisense” whereas those interacting with double stranded DNA are called “antigene”. 
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The principle of action of the antisense oligonucleotides3 (Figure 2 b) is the binding via Watson-
Crick base pairing to a complementary region on target mRNA and the formation of a duplex 
(RNA-DNA hybrid). 
In this way the RNA strand is blocked in a duplex, so to prevent the translation and subsequently 
the expression of the corresponding protein. When target proteins are disease related, this will have 
therapeutic value. Nature itself utilizes the antisense principle for the regulation of a variety of gene 
products and antisense RNA molecules have been found to be expressed intracellularly. 
For an “antisense” oligonucleotide  to be able to inhibit translation, it must reach the interior of the 
cell unaltered, so it has to be stable towards extra and intra cellular enzymes as well as able to 
traverse the cell membrane. 
Once within the cytoplasm it must bind the target mRNA with sufficient affinity and high 
specificity. 
 
 
 
Figure 2  Schematic illustration of (a) Normal gene expression. DNA is transcribed into mRNA to 
give multiple copies of the protein gene product; (b) Antisense inhibition. An antisense 
oligonucleotide binds specifically to mRNA via Watson-Crick hydrogen bonding whereby it 
inhibits translation of mRNA into protein; (c) Antigene inhibition. Transcription is inhibited by the 
binding of an antigene oligonucleotide to DNA. 
 
In another approach, the ‘antigene strategy’,4 (Figure 2c ) the transcription can be inhibited by the 
binding of an ODN to a duplex DNA via formation of triple helix through Hoogsteen (*) hydrogen 
bonds5 (Figure 3). However, many factors, including instability of triple helical complexes in cells, 
limit the efficacy of this approach. 
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Figure 3 T* A-T  and C+* G-C triplets involving Hoogsteen and Watson-Crick base pairing. 
 
DNA as diagnostics tools 
 
Due to their relative simplicity, rapidity, workability and remarkable sensitivity, DNA diagnostics 
hold the distinct position in the area of molecular in vitro diagnostics. Various aspects of DNA 
diagnostics range from PCR-based techniques, DNA microarrays, microfluidics to fluorescent in 
situ hybridization (FISH), SNP detection, DNA nanotechnology, molecular beacons, and many 
others.6 
DNA is particularly used in diagnostic as molecular beacon7 that’s a single-stranded oligonucleotide 
probe that form a stem-and-loop structure. The loop contains a sequence that is complementary to a 
target sequence, and the stem is formed by two complementary tracts flanking the loop sequence. A 
fluorophore and a quencher are covalently linked to the ends of the probe. The molecular beacons 
do not fluoresce when the probe is in its stem-and-loop form, with the quencher spatially near to the 
fluorofore, while they fluoresce brightly when the probe hybridize to the target sequence (Figure 4). 
Obviously the length of the loop and the stem has to be designed in a way to realize a probe-target 
complex more stable than the stem hybrid, consequently, the molecular beacons spontaneously form 
fluorescent probe-target hybrids.  
 
 
 
Figure 4 Molecular beacon. 
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Molecular beacons can be added to the assay mixture without carrying out gene amplification and 
fluorescence is measured in real time. The use of different molecular beacons with differently 
coloured fluorophores enable to detect different targets simultaneously in the same assay. Molecular 
beacons are extraordinarily specific, they easily discriminate target sequences that differ from one 
another by a single nucleotide substitution.  
 
DNA as nanomaterials 
 
Recently, physicists and chemists have become increasingly interested in the electronic properties 
of the DNA to be used as nanomaterial using its ability to self–assembly, a requirement essential for 
the construction of nanoscale devices. The construction of three dimensional cubes, simple switches 
and motors from DNA building blocks has already been reported.8 However, the usefulness of DNA 
in nanotechnology would enhanced considerably if it were a good electronic conductor. 
Y-shaped DNA template9 incorporating a central biotin moiety may be used to assemble nanoscale 
architectures (Figure 5), as potential to the fabrication of next-generation electronic devices. There 
are potential applications of the above and related DNA templates in the emerging field of 
nanoelectronics. 
 
 
 
Figure 5  Y-shaped DNA template with a central biotin moiety. 
 
DNA limits  
 
In diagnostic the use of synthetic ODN is limited by the inaccessibility of the nucleic acid target site 
under the conditions required for the probes to bind. Therefore, many nucleic acids (dsDNA and 
mRNA) cannot be easily analyzed using conventional DNA and RNA probes. Furthermore, the 
 9 
general applicability, for example of PCR approach, is limited by the fact that the majority of 
primer-template mismatches have no significant effect on the amplification process.10 
In addition, the practical application of ODN as useful therapeutic agents have two severe limits: 
the enzymatic degradation of ODN by cellular nucleases, and the poor cellular uptake. To address 
the issue of poor cellular uptake, a number of delivery systems have been proposed, including 
cationic liposomes,11 cationic lipids,12 and cationic polymers.13 The problem of enzymatic 
susceptibility of ODN has been partially solved by chemical modifications of ODN, like in the case 
of phosphorothioate,14 or by employing new ODN analogous, such as peptide nucleic acids (PNA)15 
or LNA.  
 
DNA modifications 
 
In order to confer resistance to cellular enzymes but still allowing the formation of stable 
duplexes/triplexes with target nucleic acids, several chemical modifications16  have been introduced 
in the oligonucleotide structure. 
The various possible sites of modification in a nucleotide are shown in Figure 6 and could involve 
the sugar-phosphate backbone and/or the nucleobases. The modifications are commonly grouped 
into three ‘generations’: 1) analogues with altered phosphate backbones, 2) modified sugars 
(especially at the 2′ position of the ribose) or unnatural bases, and 3) modified phosphate linkages 
or riboses as well as nucleotides with a completely different chemical moiety replacing the furanose 
ring. However, the modified ODNs should have  resistance to nuclease digestion, good cellular 
uptake, satisfactory hybridization affinity to the target nucleic acids, binding specificity and low 
toxicity.  
 
 
 
Figure 6 DNA’s modification sites. 
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The first generation modifications, designed to make the internucleotide linkages more resistant to 
nuclease attack, regarded the phosphodiester backbone and have led to a large variety of new ODN 
analogous, like as phosphorothioates (1a), phosphorodithioates17 (1b), methyl phosphonates (1c), 
hydroxymethyl phosphonates (2), phosphotriesters (3), phosphoramidates18 (4) (Figure 7). The 
phosphorothioate ODN, in which a sulphur atom substitutes a non-bridging oxygen in the 
phosphate backbone, resulted to be the most promising analogs in the antisense approach. 
Vitravene, 19 a phosphorothioate ODN with potent and specific anticytomegalovirus (CMV) activity, 
is the first antisense oligonucleotide based drug approved by FDA. 
 
 
 
Figura 7. Phosphate modification: first generation antisense oligonucleotides. 
 
Nucleotides with alkyl modification at the 2′ position of the ribose belong to the second generation 
modifications, among which 2'-O-methyl and 2'-O-methoxy-ethyl are the most important 
representatives (Figure 8). The significant improvements are: a reduction in general of toxicity, 
increased hybrid stability, and increased nuclease resistance. However, these desirable properties 
are counterbalanced by the fact that 2'-O-methyl RNA cannot induce RNase H cleavage of the 
target mRNA. 
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Figure 8. Second generation antisense oligonucleotide A) 2-O-methoxyethyl (MOE) B) 2-O-
methyl. 
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In the class of third generation ODN modifications, morpholino phosphoroamidates (MF), peptide 
nucleic acids (PNA) and locked nucleic acids (LNA) are three interesting RNA/DNA analogues that 
attract much attention (Figure 9). These compounds are essentially nuclease resistant while 
maintaining good hybridization affinity with their complementary mRNA. 
Effective gene knock-down by antisense MFs in vivo has been shown, and therapeutic compounds 
are being developed. One of this morpholino phosphoroamidates targets the c-myc oncogene20 and 
is currently being tested in phase I and II clinical trials by AVI BioPharma (Portland, OR, USA). 
 
N
O B
O
PO N
N
O B
O
O
O
B
N
N
H
O
O
O
O
B
O
P OO
aegPNA (b)MF (a) LNA  (c)
 
                      
Figure 9. Class of third generation ODN modifications. a) morpholino phosphoroamidates (MF), 
b) PNA (peptide nucleic acid), c) LNA ( β-D-ribo). 
 
In LNA nucleoside monomer (Figure 9c) the furanose ring being part of dioxabicyclo[2,2,1]heptane 
skeleton is locked in an N-type conformation (C3’ endo or 3E conformation). Such a 
conformational or structural pre organization of the furanose ring is an important factor for the high 
binding affinity for natural nucleic acids of these analogues. Full LNA ONs have been successfully 
used in vivo to block the translation of an RNA polymerase.21 These ONs inhibited tumor growth in 
a xenograft model with an effective concentration that was five times lower than was found 
previously for the corresponding PS-ODN. 
The most important success of the ODN chemical modifications has probably been the PNA 
(Peptide Nucleic Acids), firstly described by Nielsen et al. in 1991.22 PNAs are homomorphous  
DNA analogues in which the entire sugar phosphate backbone of DNA is replaced by a neutral and 
achiral polyamide backbone consisting of N-(2-aminoethyl) glycine (aeg) moieties (Figure 10). 
Each of the four nucleobases, adenine, cytosine, guanine, thymine (A, C, G, T), are attached to the 
backbone through a methylene carbonyl linkers. 
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Figure 10 Comparison of PNA and DNA oligomer. 
 
The particular arrangement of atoms in PNA is the same of the '6 + 3' number of bonds arrangement 
found for DNA. Considering the geometry of the DNA backbone this reveals that six bonds 
separate each nucleobase unit, while the distance between the backbone and the nucleobase is three 
bonds. Since the first reports on PNA, a large number of approaches to the synthesis of PNA 
monomers have been reported.23 In the majority of the synthetic strategies the monomer was 
disconnected about the central amide bond, a protected nucleobase acetic acid and a protected N-(2-
aminoethyl) glycine were used. 
PNAs are resistant to nucleases and proteases,24 they bind with high affinity and specificity to 
complementary RNA and DNA. 
By convention, PNAs are depicted like peptides with N-terminus at the left and C-terminus at the 
right. Being achiral, PNAs bind DNA/RNA in either parallel or antiparallel modes, the antiparallel 
mode is slightly preferred over the parallel one.25 
The orientation in which the amino terminus of PNA binds to the 5’ end of DNA is designated as 
parallel, while the orientation resulting from the amino terminus of PNA binding to the 3’ end of 
the target DNA is termed antiparallel (Figure 11). 
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Figure 11 PNA-DNA binding mode 
 
PNA synthesis 
 
PNA synthesis uses Fmoc or tBoc based chemistry as peptide synthesis.26 The four PNA monomers 
(a, t, g, c) are commercially available with either Fmoc or tBoc protecting groups on the primary 
amine and a Bhoc or Cbz protecting groups on the nucleobase. For manual PNA synthesis, 
Boc/Cbz-PNA monomers are used due to the less stringent requirement for anhydrous conditions 
during coupling reactions. For automated synthesis, Fmoc/Bhoc PNA monomers (Figure 12) are 
routinely used because the conditions for Fmoc removal are less caustic to the instrumentation 
respect to the Boc deprotection.  
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Figure 12 Fmoc/Bhoc PNA monomers. 
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The PNA automated synthesis is performed on the Perceptive Expedite 8909 from Applied 
Biosystem (Figure 13). 
 
 
 
Figure 13 Perceptive Expedite 8909. 
 
Starting from a solid support resin, PNA synthesis occurs from C-terminus to N-terminus repeating 
the base cycle depicted in Figure 14. The cycle starts with the removal of the Fmoc groups from the 
solid support with a solution of piperidine (20%) in DMF. Successively, the  protected monomer is 
coupled to the growing chain. In coupling step the carboxyl group of the Fmoc (Bhoc)-protected 
PNA monomer is activated by HATU in presence of DIPEA/Lutidine as base. This activated 
carboxyl group is coupled to an exposed reactive primary amine group (uncharged under basic 
conditions) at the end of the resin-bound PNA. A capping step with  acetic anhydride is included at 
the end of the cycle to prevent chain elongation of PNA oligomers with missing bases that leads to 
truncated PNA products.  
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Figure 14 Automated PNA synthesis on the Expedite 8909 (Cycles). 
 
Upon completion of the synthesis, the PNA is cleaved from the solid-support resin with TFA and 
simultaneously the Bhoc protecting groups are removed from the nucleobases. Also included with 
TFA in the cleavage step is m-cresol that acts as a scavenger for the released protecting groups, 
preventing undesired side reactions with the free amino groups present on the PNA oligomer. 
The PNA is then precipitated in cold diethyl ether, dried to a solid, and resuspended in water. Being 
neutral compounds, pure PNAs have a tendency for self aggregation and a low water solubility. The 
introduction of charged groups at N/C terminus, or of positive charges by modification of PNA 
backbone greatly improves their properties.27Alternatively, negative charges can be introduced, 
such as in the PNA-DNA chimeras, which show enhanced water solubility. 28 
 
PNA complex stability 
 
PNAs are able to form stable duplexes with complementary DNA and RNA. Duplexes between 
PNA and DNA or RNA are in general thermally more stable than the corresponding DNA-DNA or 
DNA-RNA duplexes.29 Very importantly, the stability of PNA-DNA duplexes are not influenced by 
the ionic strength of the medium.30 This is in contrast to the behavior of DNA-DNA (or RNA) 
duplexes, in which the stability decreases dramatically at low ionic strength because of the lack of 
counterion shielding of the phosphate backbone.30  
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Biophysical structures of PNA complexes 
 
When annealed the PNA oligomer conforms to its nucleic acid partner. The backbone of the PNA 
oligomer is flexible enough to adopt the preferred duplex conformation of its bound nucleic acid 
complement, but not so flexible to destabilize hydrogen bond formation. 
The PNA-RNA31  and PNA-DNA32 duplex structures were determined by NMR methods, while the 
structures of a PNA2:DNA triplex33 and a PNA:PNA duplex34  were solved by X-ray 
crystallography (Figure 15). In the PNA-RNA and PNA-DNA duplexes the oligonucleotide adopts 
close to its natural A-conformation and B-conformation in terms of sugar puckering, while the helix 
parameters have both A- and B-form characteristics. From these two cases it seems that the PNA is 
an excellent DNA/RNA mimic. Anyway the PNA prefer a unique, different helix form, the P-form, 
which is taking over already in the PNA2:DNA triplex and is of course fully developed in the PNA-
PNA duplex. This helix is very wide (28 Å diameter) and has a very large pitch (18 base pairs) 
unlike the “A” form of PNA:RNA duplex or the “B” form of PNA:DNA duplex.  
 
 
 
Figure 15 Structural features of PNA:RNA, PNA:DNA, PNA2:DNA triplex, PNA:PNA. The 
double helix formed by PNA:RNA and PNA:DNA resembles the form of RNA:RNA and 
DNA:DNA double helices. PNA2:DNA triplex and PNA:PNA takes on a new form called the P-
form (neither A- nor B-form). 
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PNA applications 
 
Since its introduction, an increasing number of applications of PNA technology have been 
described, confirming the high potential of PNAs in biotechnological applications. 
Applications of PNA can be divided into four main categories, namely PNA for antigene and 
antisense therapy, PNA as a tool for molecular biology and functional genomics, PNA as a probe 
for diagnosis and detection  and PNA as biosensors.35 PNAs can be used in many of the 
applications where traditional synthetic DNA or RNA have been used, but with the added benefits 
of tighter binding, greater specificity and stability. 
 
PNA as therapeutic agent: antigene and antisense strategies 
 
Antisense properties of PNA 
In antisense strategy the nucleic acid analogues can be designed to recognise and hybridise to 
complementary sequences in mRNA and thereby inhibit its translation. Normally, the PNA 
antisense effect is based on the steric blocking of either RNA processing, transport into cytoplasm, 
or translation. It has been found by in vitro translation experiments that mixed purine-pyrimidine 
PNA sequence that form PNA-RNA duplexes with the target, did not arrest translation elongation, 
indicating that the PNA was displaced by the moving ribosome. However, when homopurine targets 
are present in the translated region of the RNA, these can be targeted by homopyrimidine (bis)36 
PNAs, which form very stable PNA2-DNA triplexes that are able to arrest the ribosome during 
elongation. Triplex-forming PNAs can inhibit translation at initiation codon targets and ribosome 
elongation at codon region targets. 
Antigene properties of PNA 
Originally conceived as agents for double-stranded DNA binding, the unique properties of PNAs as 
DNA mimics were first exploited for gene therapy drug design. 
PNAs should be capable of arresting transcriptional process for their ability to form a stable triple 
helix by strand-invasion or strand displacement of a DNA duplex (Figure 16). Such complexes can 
create a structural hindrance to block the function of RNA polymerase and thus are capable of 
working as antigene agent37 causing the distortion of the DNA helix. Therefore PNA gene targeting 
at the DNA level should be very efficient. The main obstacle appears to be the access of PNA to the 
DNA under physiological conditions, which includes the presence of cations that stabilize the DNA 
double helix but reduce the rate of helix invasion by the PNA.38 
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Figure 16 Schematic drawing of the mode by which PNA binds to duplex DNA targets. PNA 
oligomers are in bold. a) Strand displacement via PNA-DNA*PNA triplex formation, b) strand 
displacement via PNA-DNA duplex formation, c) strand invasion via PNA-DNA double duplex 
formation, d) PNA*DNA-DNA triplex formation. 
 
PNA for diagnosis and detection 
 
SNP detection using PNA-directed PCR clamping 
The high affinity and specificity of PNA binding to DNA, and the inefficiency of PNA to act as a 
primer for DNA polymerases, make PNAs suitable to use in PCR techniques to reveal single-base-
pair mutation or single-nucleotide polymorphism (SNP). Basically, in the PCR clamping technique, 
at the annealing step the PNA is targeted to one of the PCR primer sites.39 The PNA, which binds to 
the primer binding site instead of the primer, effectively blocks the formation of a PCR product. 
PNA is able to discriminate between fully complementary and single-mismatch targets (mutations) 
in a mixed target PCR, because in the case of mismatches the PNA/DNA hybrid has a melting 
temperature much lower than the corresponding fully complementary one. Hence the binding of 
primer will be favoured to out-compete PNA annealing. Consequently, mutated sequences will be 
preferentially amplified (Figure 17). 
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Figure 17 Mutation analysis using PNA-directed PCR clamping: schematic representation of the 
strategy for the PCR cycle involving PNA-directed clamping. In the case of the normal (wild-type) 
DNA, the bound PNA will sterically hinder annealing of a partially overlapping primer sequence, 
thus preventing the normal sequence from appropriate PCR amplification. In the case of mutant 
alleles, the melting temperature of the PNA/DNA is reduced and the primer can out-compete PNA 
annealing to carry on preferential amplification of mutant sequences. 
 
PNA as molecular beacon 
PNA molecular beacon (MB) were successfully used to detect rRNA in solution and in whole cells40 
rRNA molecules have been used widely as target molecules for rapid monitoring of changes in 
microbial population abundance. In the case of the detection in whole cells fluorescence in situ 
hybridization (FISH) experiments were perfomed. FISH results with the PNA molecular beacons 
were superior to those with the DNA one: the hybridization kinetics were much faster, the signal-to-
noise ratio was much higher, and the specificity was much better.  
In addition,  a real-time PCR assay using PNA molecular beacons to discriminate between the A-
allele and C-allele of a SNP in exon 6 of the XPD gene41 has been developed. 
  
PNA probe for microarray 
The analysis of biomolecules using microarrays and other biosensors has a significant role in 
molecular biotechnology.  By combining peptide nucleic acid (PNA) microarray chips42 as probes 
for hybridization of DNA sequences with time-of-flight secondary ion mass spectrometry (TOF-
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SIMS) for detecting complementary hybridization with high sensitivity, label-free and PCR-free 
DNA diagnostics should become possible (Figure 18). TOF-SIMS is a technique that can identify 
the presence of phosphates in a molecular surface layer with high sensitivity in the attomole range. 
The detection of hybridization with unmodified genomic DNA becomes possible without any 
amplification or labeling step needed. 
 
 
 
Figure 18 Label-free detection by TOF-SIMS analysis. A primary ion beam hits the surface, from 
which secondary ions, including phosphate fragments, are released. PNA does not contain 
phosphates. Therefore,  phosphate ions are visible in the mass spectrum of a PNA-microarray only 
upon hybridisation of nucleic acids.  
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PART 1: Dendrimeric system based on ODN and analogues 
 
 
Dendrimers based on poly-amidoamine (PAMAM) were the first and most extensively studied 
family of dendrimers which provided a large variety of biomedical applications (i.e., the delivery of 
active pharmaceuticals, imaging agents, or gene transfection).43 Using the four base recognition of 
the DNA many researchers were interested in dendrimeric systems based on DNA in order to 
develop new drug delivery system or new nanomaterials. 
The huge interest in nanomaterials is driven by their many desirable properties. In particular, the 
ability to tailor the size and structure and hence the properties of nanomaterials offers excellent 
prospects for designing novel sensing systems, enhancing the performance of bioanalytical assays. 
Thanks to the specificity of assembly of nucleic acid strands, oligonucleotides can be used as 
generic instead of genetic material.44 The possibility to form extended oligonucleotidic systems 
with well-defined sizes, shapes, branching length/density and their surface functionality45 could be 
of eminent interest in certain medical applications such as drug delivery, gene transfection, and 
imaging.  
In order to develop ODN dendrimers, with enhanced thermal stability and good nuclease resistance, 
to be used for drug delivery or diagnostic applications, we realised two dendrimeric systems: a 
monomolecular system based on PNA (A, Figure 19) and a bimolecular one based on PNA and 
DNA building blocks (B, Figure 19). 
Both systems have the ability to form a three-dimensional network by means of specific W-C base 
pairing. 
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Figure 19 Schematic view of the dendrimeric systems. 
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1.1 Monomolecular PNA dendrimer 
 
The first dendrimeric system realized  is a PNA-based monomolecular tridendron formed by an 
autoassembling PNA (a, Figure 20) with the following  sequence: (Ac-t-t-t-t-t)2-K-a-a-a-a-a-KNH2 
(1). The dendrimeric system realized, that can self-assembly in the way showed in Figure 20 (b), 
should have the ability to form a three-dimensional network by specific W-C base pairing, to obtain 
a gel for encapsulating drugs.  
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Figure 20 a) Chemical structure of PNA-based monomolecular tridendron, b) Schematic view of 
the self-assembly system (red: poly-adenine tract; blue: poly-thymine tracts; magenta: lysines; 
green shadowing: PNA-PNA double helices). 
 
The PNA tridendron (1) has been  assembled on an automatic synthesizer (Figure 14) using 
standard 2 µmol-scale protocol and Fmoc chemistry, following the synthetic procedure described in 
Scheme 1. 
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Scheme 1  PNA 1 tridendron synthesis. 
 
Starting from the C-terminus, PNA tridendron is constituted by a Lysine residue, a poly-adenine 
branch (a5), another Lysine in the middle of the sequence and two poly-thymine branches (t5), 
assembled simultaneously on both amino groups of the central Lysine which was doubly Fmoc-
protected. The C-terminal Lysine was useful to improve the final product solubility.  
After removal and quantification of the final Fmoc groups both N-terminal thymine NH2 were 
acetylated; the oligomer was cleaved and deprotected by acidic treatment (TFA:m-cresol, 4:1, v/v). 
The PNA tridendron was purified on RP-HPLC and characterized by LC-ESIMS (Figure 21). 
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Figure 21 LC-ESI MS monomolecular PNA tridendron. 
 
The PNA was lyophilised, dissolved in a known amount of milliQ water and quantified by UV 
measurements (T= 85 °C, absorbance value at λ=260 nm). The epsilon used for the quantification of 
the oligo is ε260=154500 M-1 and was calculated using the molar extinction coefficients as follows: 
a, 15.4; t, 8.8. UV quantification of the PNA provided the following value: 15 mer = 395 nmol (1.7 
mg, 24 % yield). 
A detailed spectroscopic study was performed on the annealed PNA to verify the stability of the 
system as well as the formation of the three-dimensional network, allowing to elucidate its 
thermodynamic and structural properties. Circular dichroism (CD) spectum of the annealed PNA is 
shown in  Figure 22. Even if single strand PNA, being achiral, doesn’t show CD signal, when it 
forms duplex or triplex structures exhibits a significant signal. In our case a positive band centred at 
275 nm is indicative of a duplex formation. 
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Figure 22 CD spectrum of PNA tridendron 1, 8 µM in H2O, 20 °C. 
 
After the annealing of the system A (Figure 19), performed by dissolving the oligomer in milliQ 
water, heating the solution at 90 °C (5 min) and then allowing to cool slowly to room temperature, 
we proceeded to determine its thermal stability by UV melting experiments. The Tm of the self-
assembly PNA system was 58 °C at 4 µM concentration (Figure 23 ). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 23 UV melting of monomolecular PNA system. 
 
By recording UV melting curves at different PNA concentrations, we observed a logarithmic 
dependence of the melting temperature from concentration (Figure 24), with an increasing of the Tm 
value from 54.9 °C to 59.5 °C, going from 1 to 17 µM. 
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Figure 24 Dependence of Tm from concentration of PNA tridendron. 
 
Furthermore, a linear self-complementary PNA, Ac-t5-K-a5-KNH2 (2), was realized as control. It 
has been synthesised in analogy to PNA tridendron 1 (2 µmol scale, Fmoc chemistry), purified on 
RP-HPLC and characterized by LC-ESIMS (Figure 25). The UV quantification of the PNA 2 
provided a 30 % overall yield (600 nmol, 1.9 mg), using the ε260 of 111500 M-1 for the a5t5 sequence 
of this oligomer. In Figure 26 is reported the UV melting profile of a 5 µM solution of PNA 2 
(Tm=54 °C). Contrarily to PNA tridendron 1, in this case no significant changes in the Tm of 
oligomer 2 was revealed, by varying its concentration from 1 to 30 µM. All these findings support 
the formation of a three-dimensional network for system A. 
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Figure 25 LC-ESIMS profile of Ac-t5-K-a5-KNH2 
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Figure 26 UV melting curve of  Ac-t5-K-a5-KNH2 (2). 
 
To exclude the possibility that the central lysine in system A could interrupt the cooperativity of the 
duplexes formed by the tridendron arms, leading to the formation of a less stable three-dimensional 
network, we synthesized, as controls, two linear PNA strands having the sequences of the PNA 
tridendron arms: H-G-a5-KNH2 (3) and H-G-t5-KKNH2 (4). Oligomers 3 and 4 were synthesized on 
solid phase using standard 2 µmol-scale protocol, purified on RP-HPLC and characterized by LC-
ESIMS (Figures 27 and 28). 
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Figure 27 LC-ESIMS of H-G-a5-KNH2 (3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 28 LC-ESI MS of H-G-t5-KKNH2 (4). 
 
The UV quantification of the PNA 3 and 4 provided the following value: 750 nmol, 1.2 mg, 37 % 
overall yield for 3 (ε260=68500 M-1); 650 nmol, 1.0 mg, 33 % overall yield for 4 (ε260=43000 M-1). 
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The UV melting curve of the 1:1 complex of 3 and 4 showed a Tm value of only 19 °C at 4 uM 
(Figure 29) respect to 58 °C for tridendron 1 at the same concentration, demonstrating that the 
lysine core in system A doesn’t create a great issue for the cooperativity of the duplexes formation. 
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Figure 29 UV melting curves of 1:1 a5/t5 complex. 
 
Since the dimension of the monomolecular self-assembly dendrimeric system is not easily 
controllable, if not acting on the concentration of the component (1), we also designed and realized 
a bimolecular system (B, Figure 19) constituted of PNA and DNA building blocks. 
A two component system should give the possibility to perform a fine control of the shape and the 
dimension of the three-dimensional dendrimeric network. 
 
1.2 Bimolecular PNA/DNA dendrimer 
 
The bimolecular dendrimeric system B (Figure 19), made up of a PNA tridendron with a not self-
assembly sequence and a DNA crosslinker, has the ability to form a three-dimensional network 
exploiting the formation of PNA/DNA duplexes. In Figure 30 is shown a schematic view of the 
bimolecular system realized. 
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Figure 30 PNA/DNA dendrimeric system B. Red: PNA arm at C-terminus; blue: 2 arms of PNA 
having the same sequence; magenta: lysines; light blue: DNA crosslinker; green shadowing: PNA-
DNA double helix. 
 
The PNA tridendron sequence is (Ac-a-a-t-g-g)2- K-a-c-a-a-c-KNH2 (5), while the DNA crosslinker 
one is 5’C C A T T C G T T C T3’ (6). The DNA was complementary to two of the PNA tridendron 
branches. 
PNA 5 was synthesized on solid phase synthesis by using Fmoc chemistry and 2 µmol-scale 
standard protocol. The crude PNA was purified on RP-HPLC and characterized by ESI-MS (Figure 
31).  
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Figure 31 LC-ESIMS profile of the PNA tridendron 5. 
 
Crosslinker 6 was assembled on automatic synthesizer using standard 1 µmol-scale protocol and 
phosphoroamidite chemistry. After cleavage and deprotection, the DNA oligo was purified by 
HPLC using an anionic exchange column, desalted by gel filtration, and characterized by MALDI-
TOF spectrometry (data not shown). 
The oligomers 5 and 6 were lyophilised, dissolved in a known amount of milliQ water and 
quantified by UV measurements (T= 85 °C, absorbance value at λ=260 nm). UV quantification of 5 
(c2a7t2g4) provided 500 nmol of the PNA (2.1 mg, 25 % yield), using ε260=173100 M-1. UV 
quantification of DNA 6 was performed using the ε260=104700 M-1, calculated considering as 
extinction coefficients for the single base the following values: A, 15.4; T, 8.8; G, 11.7; C, 7.3 
mM-1. In this way 586 nmol (1.9 mg, 58.6 % yield) of purified product was estimated. 
We realized the bimolecular system B with the aim to investigate: 1) the PNA/DNA duplex 
formation; 2) the optimal crosslinker/tridendron ratio to obtain the most extensive network 
formation; 3) the gelation process. 
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We verified PNA/DNA duplex formation by CD experiments using a tandem cell (Figure 32) which 
minimize errors relative to the obtainment of the exact concentration of both PNA and DNA before 
and after the complex formation. 
 
 
 
Figure 32 Hellma tandem cell. 
 
Figure 33 shows the sum CD spectrum (red line) of the two separated strands (PNA tridendron in 
one compartment and DNA in the other one before mixing) and the complex spectrum (blue line) 
obtained after mixing the two samples; both spectra were recorded at T=20 °C in H2O and using a 
1:2.5 tridendron/crosslinker ratio. As shown in Figure 33, there is a significant difference between 
the two spectra with an increase of intensity and shift to lower wavelength of the band at 280 nm, a 
clear evidence of duplex formation.  
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Figure 33 Sum (red line) and Mix (blue line) CD spectra of Tridendron 5/Crosslinker 6, 1:2.5, 20 
°C in H2O. 
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A kinetic study of the complex formation for the bimolecular system B was performed by CD 
experiments, recording CD spectra at different times, after mixing the two strands. In Figure 34 the 
CD signal variation at 240 nm and 275 nm was reported in function of time: after 100 min the 
recorded CD signal presented more or less the same value for the two wavelengths, suggesting the 
complete formation of the bimolecular system and hence of the three-dimensional network. 
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Figure 34 CD kinetic studies on bimolecular system B. 
 
Being the bimolecular system formed by two components, it would be fundamental to find the 
optimal ratio of the two parts to obtain the most extensive and stable network. The hypothesis about 
the equilibrium of the network formation is reported in Figure 35: at low concentration of 
crosslinker there will be a certain amount of duplex formed and some free tridendron. In excess of 
DNA crosslinker, all the tridendron sites will be saturated and there will be some free crosslinker 
ends. In these two extreme cases we would expect for the system B a lower stability than in the case 
of the optimal crosslinker/tridendron ratio, in which there will be the maximum amount of duplex 
formed and consequently of the network formation. 
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Figure 35 Equilibrium network formation. 
 
In order to find the optimal crosslinker/tridendron ratio for obtaining the most extensive network 
formation, we performed UV melting studies on the annealed strands in H2O with experiments in 
which the tridendron concentration was fixed and the crosslinker one was gradually increased. 
The table contained in Figure 36 summarizes Tm values, calculated with the first derivatives 
method, at the corresponding crosslinker/tridendron ratios. By reporting Tm values vs 
crosslinker/tridendron ratios, we obtained a bell curve (Figure 36) showing a maximum at 2:1 ratio, 
which is thus the best one leading to the most extensive formation of the three-dimensional net. 
These data are in agreement with the aforementioned hypothesis on the equilibrium network 
formation. 
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Figure 36 Table and bell curve of Tm vs crosslinker/tridendron ratio. 
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In Figure 37 the UV melting profile of a solution contained the PNA tridendron 5 and the DNA 
crosslinker 6 at the best ratio (1:2) is reported. 
 
 
 
Figure 37 UV melting curve of tridendron/crosslinker, 1:2. 
 
1.3 Preliminary gelation test. 
 
We continued our studies testing the ability of the two new dendrimeric systems to realize hydro 
gels, exploiting the formation of a three-dimensional network obtained by specific W-C base 
pairing, to be used in various applications, like as for encapsulating drugs. Preliminary gelation tests 
were performed on both the systems A and B by dissolving the lyophilized oligomers in 200 µL 
water, heating at 90 °C for 5 minutes, slowly cooling at room temperature and finally storing at 4 
°C for 12 hours. For system A, the tests were performed using 50µM and 200µM concentrations at 
20 °C. For system B, we used the optimal ratio tridendron/crosslinker, of 1:2, 50 µM and 200 µM 
overall concentrations at 20 °C, 400 µM and 600 µM concentrations at 4°C. 
In the case of system B, we observed the formation of a labile layer on the bottom of the glass tube 
as showed in the picture below (Figure 38). 
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Figure 38 Preliminary gelation test on system B. 
 
1.4 Microrheology experiments on systems A and B. 
 
In general, the aim of microrheology, performed by using the Multiple Particle Tracking (MPT) 
technique, is to study the viscoelastic properties of materials, exploiting the Brownian motion of 
micron-sized particles embedded in samples.46 A typical experimental setup employs 
videomicroscopy to track the Brownian motion of micron-sized, inert, fluorescent particles.47 
Information about the local mechanical properties of the sample is then obtained by performing 
statistical analysis of the tracer particle motion. 
For both the systems A and B, a solution of fluorescent polystyrene beads (diameter, 0.55 µm) was 
added to the sample solutions, obtained as described for the gelation tests. 80µL of the resulting 
mixture were fixed on a glass slides and stored 10 minutes at 4°C to perform microrheology 
experiments. 
We performed and processed the motion of these fluorescent particles in our dendrimeric systems to 
obtain information on the rheological behaviour of the systems, as well as of sterical and chemical 
interactions between the particles and the network. 
The experiments on the dendrimeric systems were performed as follows: for 15 different zones on 
the glass slides, a stack of 250 images of the beads were recorded on a digital microscope Olimpus 
1X51 (Schematic view Figure 39). For each of the 250 images the computer calculates the number 
of beads, their position in the recorded image by using a 2-D particle tracking algoritm. 
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Figure 39 Microrheology apparatus 
 
The results obtained were processed by an home made Matlab program, allowing us to obtain, by 
the generalized Stokes-Einstein equation, the dynamic parameters G ' (elastic modulus) and G'' 
(viscosity modulus), which, reported in graph vs frequency, showed us the behaviour of the medium 
(G’<G’’=sol, G’>G’’= gel, G’= G’’ sol-gel equilibrium.). 
From the data analysis the behaviour of the dendrimeric systems realized are typical of a polymer 
solution. Indeed, in the case of bimolecular system, shown in Figure 40 G’’>G’ in all the 
investigated frequency range, and, furthermore, both the dynamic moduli show a dependence upon 
the frequency as typical of a polymer solution. 
 
 
 
 
 
 
 
Figure 38 
 
Figure 40 Bimolecular system microrheology test . 
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1.5 Conclusion 
 
This part of thesis describes kinetic and thermodynamic study relative to the formation of PNA and 
PNA/DNA dendrimers. We realized two kind of systems: a PNA-based monomolecular system (A, 
Figure 19) and a PNA/DNA bimolecular one (B, Figure 19). The system A is formed exclusively of 
a three branched PNA (PNA tridendron), while the bimolecular system B is made of a PNA tri-
dendron with a mixed sequence, and a DNA crosslinker. Both systems have the ability to form a 
three-dimensional network by means of specific W-C hybridization. 
The components of the two systems were realized in solid phase by using Fmoc chemistry for the 
PNA, and phosphoroamidite chemistry in the case of the DNA. All the oligomers, deprotected and 
detached from the solid support, were purified by HPLC and characterized by MALDI-TOF and 
ESI-MS. A detailed spectroscopic study was performed on both systems to verify the formation of 
the oligonucleotidic network allowing us to elucidate its thermodynamic and kinetic properties. 
Finally, we proceeded with microrheology experiments to test the ability of the systems to realize 
hydro gels for encapsulating drugs. 
Unfortunately our system was not able to form stable hydro gels , probably due to the not so high 
concentration realized. Thus, other gelation experiments, using greater concentrations of the 
components, will be under investigation and as a consequence it will require large scale synthesis of 
PNA and DNA components. 
Furthermore, we will explore other dendrimeric systems, using for example tridendron with arms 
more than 5 base in length, to verify if in the previous analyzed cases (A and B systems Figure 19) 
the sol behaviour was due to the concentration used or to the inability to form extended three-
dimensional network with short arms. 
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1.6 Materials and methods 
 
Chemicals 
Fmoc-Gly-OH, HATU, Fmoc-Lys(Boc)-OH, Fmoc-Lys(Fmoc)-OH, and PyBOP were purchased 
from Novabiochem. Anhydroscan DMF and NMP were from LabScan. Piperidine was from 
Biosolve. Solvents for HPLC chromatography and acetic anhydride were from Reidel-de Haën. 
TFA, Rink-amide resin, were Fluka. Perspective Biosystem PAL-Peg resin, PNA kit (Fmoc/Bhoc 
monomers, HATU activator, Base solution, Wash B, DIEA, Cap Solution, Deblock solution) was 
purchased from PRIMM (Milan, Italy). TFA (for HPLC) were from Romil. 
 
Apparatus  
 
aegPNA oligomers were assembled on solid-phase with an Applied Biosystems Expedite 8909 
oligosynthesizer. 
 
Crude samples containing PNA oligomers were centrifuged for 4 min at 4000 rpm (Z 200 A, 
Hermle). 
 
Products were analysed by LC-MS, performed on an MSQ mass spectrometer (ThermoElectron, 
Milan, Italy) equipped with an ESI source operating at 3 kV needle voltage and 320 °C, and with a 
complete Surveyor HPLC system, comprising an MS pump, an autosampler, and a PDA detector, 
by using a Phenomenex Jupiter C18 300 Å (5 µm, 4.6×150 mm) column. Gradient elution was 
performed at 40 °C (monitoring at 260 nm) by building up a gradient starting with buffer A (0.05% 
TFA in water) and applying buffer B (0.05% TFA in acetonitrile) with a flow rate of 0.8 ml/min. 
 
Semi-preparative purifications were performed by RP-HPLC on a Shimadzu LC-8A, equipped with 
an SPD-10A VP UV/Vis detector, and on a Hewlett Packard/Agilent 1100 series, equipped with a 
diode array detector, by using a Phenomenex Juppiter C18 300 Å (10 µm, 10×250 mm) column. 
Gradient elution was performed at 45 °C (monitoring at 260 nm) by building up a gradient starting 
with buffer A (0.1% TFA in water) and applying buffer B (0.1% TFA in acetonitrile) with a flow 
rate of 4 ml/min. 
 
Samples containing PNAs (crude or purified), were lyophilized in a FD4 Freeze Dryer (Heto Lab 
Equipment) for 16 hours. 
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Circular dichroism (CD) spectra were obtained at 20 °C on a Jasco J-810 spectropolarimeter using 
1-cm cuvette and tandem cuvette quartz (Hellma). 
Tandem cell, containing two compartments separated by a quartz window (2 × 4.375 mm, Suprasil 
quartz, Hellma). CD spectra parameters were: spectral window 320-200 nm, data pitch 2 nm, band 
width 2 nm, response 4 sec, scanning speed 50 nm/min, 3 accumulations. 
 
Ultraviolet (UV) spectra and UV melting experiments were recorded on a UV-Vis Jasco model V-
550 spectrophotometer equipped with a Peltier ETC-505T temperature controller using 1-cm quartz 
cuvette (Hellma). 
 
Microrheology experiments were performed on an Olympus 1x51 microscope (10x, 60x, 100x 
lenses) equipped with a Hg lamp and a camera Princeton Instrumentation Micromax 5MHz (model 
vt-133). 
 
Solid phase synthesis of oligomers 1-5  
 
Solid support functionalization and manual solid-phase oligomerizations were carried out in short 
PP columns (4 ml) equipped with a PTFE filter, a stopcock and a cap. Solid support used were 
PalPegPs (0.16 NH2/g) resin and Rink-amide one (0.48 mmol NH2/g, 128 mg), both functionalized 
with a lysine residue.  The Rink-amide resin was functionalized with a lysine (Fmoc-Lys(Boc)-
OH), (0.5 eq, 14.8 mg, 32 µmol) using PyBOP (0.5 eq, 16.8 mg, 32 µmol) as activating agent and 
DIEA (1 eq, 12 µL, 64 µmol) as base for 30 min at room temperature. Capping of the unreacted 
amino groups was performed with Ac2O (20%)/ DIEA (5%) in DMF. Loading of the resin was 
checked by measuring the absorbance of the released Fmoc group (ε301=7800, quantitative yield) 
after treatment with a solution of piperidine (30%) in DMF (UV Fmoc test) and resulted reduced to 
0.25 mmol/g respect to the initial functionalization. Automatic solid-phase assembly of the 
aegPNAs was performed on an Expedite 8909 Nucleic Acid Synthesis System using a standard 2 
µmol-scale protocol and Fmoc chemistry leaving the final Fmoc on in order to evaluate SPS yields 
by UV Fmoc test. A glycine residue (3 eq) was attached to the N-terminus of the oligomers (3,4) by 
using PyBOP (3 eq)/DIEA (6 eq) as activating system in DMF. After removal and quantification of 
the Fmoc group, all oligomers were cleaved from the resin and deprotected under acidic conditions 
(TFA/m-cresol 4:1 v/v). The oligomers were isolated by precipitation with cold diethyl ether, 
centrifugation and lyophilization. Purified oligomers (semipreparative HPLC) were quantified and 
characterised by LC-ESIMS.  
 41 
 
Ac-(t5)2-K-a5-K-NH2 (1) Standard aegPNA was assembled on PAL-PegPS-K-NH2 resin (0.16 
mmol/g, 2µmol, 12.5 mg) on the automatic synthesizer. The synthesis proceeded till the first poly 
adenine tract on the synthesizer then manually was added Fmoc-Lys(Fmoc)-OH (8 eq) HATU (7.2 
eq)/DIEA (8 eq), performing a double coupling. Capping of the unreacted amino groups with (5% 
Ac2O, 6% lutidine in DMF) and then the deblock (25% piperidine in DMF) to remove both the 
Fmoc groups, were performed. The synthesis continued on the automatic synthesizer till the end. 
After the synthesis was complete the final Fmoc was left on and removed manually to perform 
Fmoc UV test, at the end the free amino group were acetylated. The cleaved and deprotected 
oligomer was purified by semipreparative RP-HPLC using a linear gradient of 10% (for 5 min) to 
20% B in A over 35 min: tR=27.7 min. The purified yield of Ac-(t5)2-K-a5-K-NH2 was of 24%. ESI-
MS (Figure 21) m/z: 1463.85 (found), 1466.33 (expected for [M+3H]3+), m/z: 1097.88 (found), 
1099.75 (expected for [M+4H]4+). 
 
Ac-t5-K-a5-KKNH2 (2) was assembled on automatic synthetizer on Rink-amide-K-NH2 resin (0.25 
mmol/g, 2µmol, 8 mg) using the standard Fmoc protocol used for sequence 1. After cleavage and 
deprotection, the oligomer 2 was purified by semipreparative RP-HPLC using a linear gradient of 
7% (for 5 min) to 22% B in A over 20 min:  tR=18.0 min; ESI-MS (Figure 25) m/z: 1053.13 
(found), 1051.01 (expected for [M+3H]3+), m/z: 1576.80 (found), 1575.90 (expected for [M+2H]2+).  
 
H-G-a5-KNH2 (3) was assembled manually on Rink-amide-K-NH2 resin (0.25 mmol/g, 2µmol, 8 
mg) using the following protocol: 0.1 M Fmoc-a(Bhoc)-OH monomer in NMP (40 µl, 8 µmol, 4 
eq), 0.18 M HATU in DMF (40 µl, 8 µmol, 4 eq) and base solution [0.2 M Dipea, 0.3 M Lutidine] 
(40 µl, 8 µmol, 4 eq) in DMF. Preactivation (2 minutes) of the monomer, HATU and base solution 
was performed, then the mixture was added to the resin, and the coupling was left for 15 min with 
shaking at room temperature. 
Successively, unreacted amino groups were capped with PNA Cap solution for 5 min. Fmoc 
removal was accomplished with PNA Deblock solution (5 min) and was monitored for every step 
by UV measurements: average yield for the five steps was 90% . After last coupling with the 
glycine, oligomer was cleaved from the resin and deprotected under acidic conditions (TFA/m-
cresol 4:1 v/v) and isolated by precipitation with cold diethyl ether, centrifugation and 
lyophilization. The oligomer was purified by semipreparative RP-HPLC using a linear gradient of 
1% (for 5 min) to 18% B in A over 30 min: tR=20.2 min; and characterised by LC-ESIMS (Figure 
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27) m/z: 526.57 (found), 526.72(expected for [M+3H]3+ m/z: 790.38 (found), 789.58 (expected for 
[M+2H]2+).  
 
G-t5-KKNH2 (4) was obtained analogously to sequence 3, purified by RP-HPLC using  5% (for 5 
min) to 22% B in A over 30 min: tR=26.8 min; characterized by ESI-MS (Figure 28) m/z: 1661.8 
(found), 1661.64 (expected for [M+H] +). m/z: 831.8 (found), 831.76 (expected for [M+2H]2+). 
 
(Ac-a-a-t-g-g)2-K-a-c-a-a-c-KNH2 (5) was obtained analogously to sequence 1, purified by 
semipreparative RP-HPLC using a linear gradient of 8% (for 5 min) to 18% B in A over 35 min: 
tR=24.4 min, characterized by LC-ESI MS (Figure 31);  m/z: 1021.15 (found), 1122.2 (expected for 
[M+4H]4+), m/z: 1494.06 (found), 1492.97 (expected for [M+3H]3+).  
 
The synthesis of 5’C-C-A-T-T-C-G-T-T-C-T3’(6) was performed on an Expedite 8909 synthesizer 
(ABI/Perceptive Biosystems), using standard phosphoramidite chemistry and 1 µmole scale 
protocol. DNA synthesis was carried out in 3' to 5' direction using, as solid support, CPG 500 Å 
resin (40 umol/g, 1 umol), functionalized with the first 3'-hydroxyl-5'-Dimethoxytrityl-nucleoside. 
After deprotection and cleavage from the solid support with ammonia solution (55 °C, 15h), the 
crude chimeric oligomer was purified by HPLC on a Nucleogel SAX column (Machery Nagel SAX 
4.6x50 mm) eluted with linear gradients of KCl (0-100%) in 20 mM K2HPO4, pH 7.0, 20 % 
CH3CN. The major peak collected was liophylized, dissolved in 2.5 ml of milliQ water and desalted  
by gel filtration on a NAP-25 column. Desalted oligo was quantified by UV measurerements and 
characterized by MALDI-TOF m/z : 3294 (found), 3299 expected for MH+. 
 
UV and CD studies 
Purified oligomers were dissolved in a known amount of milliQ water and quantified by UV 
measurements (T=85 °C, absorbance value at λ=260 nm). The epsilon used for the quantification of 
the oligomers was calculated using the molar extinction coefficient of aegPNA monomers and of 
DNA one in the case of the crosslinker. 
Annealing of all PNA oligomers with complementary part was performed by mixing amounts of the 
two strands to achieve duplex of the desiderated concentration. The solution was heated at 85 °C (5 
min) and then allowed to cool slowly to room temperature. 
Thermal melting curves  were obtained by recording the UV absorbance at 260 nm while the 
temperature was ramped from 20 to 90 °C at a rate of 0.5°C/min. Tm values, calculated by the first 
derivative method, were reported . 
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CD spectra were recorded from 320 to 200 nm at 20°C: scan speed 50 nm/min, data pitch 2 nm, 
band width 2 nm, response 4 sec, 3 accumulations. 
 
Michrorheology experiments. 
The samples for michrorheology experiments for both systems A and B were obtained by 
dissolving the lyophilized oligomers in 200 µL water, heating at 90 °C for 5 minutes, slowly 
cooling at room temperature and finally storing at 4 °C for 12 hours. 
The mixtures were embedded with 3 µL of diluted solution of fluorescent polystyrene beads (0.55 
µm). The beads are molecular probe with 0.2% of the solid part in solution. 80 µL of each sample 
were fixed in a chamber on a glass slides to perform microrheology experiments at microscope. 
For system A, the tests were performed using 50µM and 200µM concentrations at 20 °C. For 
system B, we used the optimal ratio tridendron/crosslinker, of 1:2, 50 µM and 200 µM overall 
concentrations at 20 °C, 400 µM and 600 µM concentrations at 4°C. 
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PART 2: Synthesis and hybridization studies of  new oligonucleotidic analogous.  
 
 
Aminoethylglycyl peptide nucleic acids (aegPNAs 1, Figure 41) emerged more than a decade ago 
as strong and specific DNA/RNA binding agents, triggering much research interest into the 
development of PNA based antisense/antigene therapeutics or diagnostics48 thanks to their 
remarkable properties. Many efforts have mainly been directed towards the refinement of aegPNA 
properties such as binding affinity to DNA/RNA, water solubility, cellular uptake and 
discrimination between parallel and antiparallel binding modes. Different PNA modifications are 
widely described in the scientific literature,49-56 having met in some cases with success. 
The most explored PNA modifications regarded the aminoethylglycine backbone and the methylene 
carbonyl linker (1st generation modifications). In the 1st generation modifications the only tolerated 
substitution regards the α-position of the glycine. For example, substitution of the glycine with an 
alanine (D or L) resulted in a slightly lower binding affinity towards DNA.50Introduction of a D-
lysine resulted in a slight increase of Tm in the binding to DNA, while the L-isomer had the opposite 
effect. 53 
In addition, much work has been devoted to investigate various cyclic backbone-based PNAs49,52-54, 
56
 (2nd generation modifications) with the goal of increasing the selectivity or strength of interaction 
with natural nucleic acids. This class of modifications, by connecting different parts of the PNA 
backbone, introduces conformational restrictions and stereocenters into the polymer which can 
present remarkable hybridization properties. Among these kind of modifications aminoprolyl PNA 
containing oligomers are very interesting.51-54 aegPNAs with a single aminoprolyl PNA unit at N-
terminus showed discrimination of antiparallel vs parallel binding to DNA. Another class of 
interesting PNA analogues is based on a diaminoacid backbone carrying the nucleobase by means 
of an amidic bond to one amino group. In particular, it was recently reported that an oligo thymine 
PNA analogue based on D- or L-ornithine (3, Figure 41) binds to RNA by forming triple helices.55 
In this context we report our investigation about novel chiral PNA analogues, focusing the attention 
not only to the synthetic strategies but also to the binding studies towards natural and non-natural 
targets. 
In our research for the development of new ODN-like drugs or diagnostics, we designed and 
realized a chiral nucleo-γ-peptide, dabPNA (2, Figure 41), isomer of the aegPNA unit (1, Figure 
41) and characterized by a 2,4-diaminobutyric acid (DABA)-based backbone carrying the 
carboxymethylated nucleobase on its α amino group. 
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Figure 41 Chemical structure of aegPNA (1), dabPNA (2), ornPNA (3). 
 
Differently from aegPNA monomers, dabPNA (2 Figure 41) presents a shorter backbone (3C 
between the nitrogen atom and the carbonyl) and an enhanced distance between the nucleobase and 
the backbone, i.e. 3 atoms (1N+2C) instead of 2C in aegPNAs. Furthermore, in comparison with 
ornPNA (3) that binds to RNA forming a stable triplex, DABA-based PNA has a methylene group 
less in the backbone.  
Our interest to the presented dabPNA arises from the possibility to obtain new molecules able to 
bind DNA and RNA for therapeutical or diagnostic applications. Furthermore, this research was 
supported by the known stability of γ-peptides to enzymatic degradation and also by the proposal 
formulated by Meierhenrich et al.57DABA-based PNAs as prebiotic material in a primordial “PNA 
world” that would have preceded our present-day “two-polymer world”. This hypothesis followed 
the recovery of DABA and other diaminoacids57 in the extraterrestrial soil of the Murchison 
meteorite together with the DNA purine and pyrimidine bases.58 
 
 
2.1 Synthesis and oligomerization of tL-dab monomer, and binding studies on (tL-dab)12 oligomer 
 
The L-enantiomer of the natural diaminobutyric acid, was chosen, as starting material for the 
synthesis of the new monomer, in analogy to the L-ornithine-based PNAs, proposed by Petersen et 
al.59 The thymine containing monomer was synthesised starting from the commercially available 
Boc-(L)-DAB(Fmoc)-OH diaminoacid (1, Scheme 2). In the first synthetic step the Boc group was 
selectively removed with trifluoroacetic acid (TFA) to give the free amino group in α-position. The 
obtained product 2, characterized by 1H NMR and LC-ESIMS, was coupled with the thymine-1-
acetic acid using HATU/DIEA/TMP as activating system in DMF leading to the compound 4 
(Scheme 2) in 72 % yield. 
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Scheme 2 Synthesis of tL-dab monomer. 
 
The Fmoc-protected monomer 4 was purified by precipitations and  characterized by 1H/13C NMR 
and LC-ESIMS, shown in Figure 42.  
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Figure 42 LC-ESIMS of tL-dab monomer. 
 
The new monomer 4 was oligomerized manually on solid phase to the corresponding dabPNA 
dodecamer (5, Table 1) as showed in scheme 3. Since the base-mediated deprotonation of the 
carboxylic group and the time for its preactivation in basic conditions are critical points to avoid 
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racemization during the amidation of carboxylic acids with a chiral carbon in α-position,60,61the 
coupling conditions we chose made use of a mild base (TMP) and HATU as an activator, without 
preactivation, following the procedure introduced by Sforza et al.61  
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Scheme 3 Synthesis of H-G-(tL-dab)12K-NH2 oligomer. 
 
The manual synthesis of the oligomer 5 allowed us to check, by UV Fmoc test, the coupling 
efficiency which was high in the first six steps (about 96%) and decreased gradually from 96% to 
70% in the last six steps, probably because of the enhanced aggregation tendency of the increasing 
homo thymine chain. L-lysine and glycine residues were incorporated in the strand at C and N 
termini, respectively, to improve the solubility of the homo thymine polymer (overall yield: 24%). 
After cleavage and deprotection, the oligomer 5 was purified by semipreparative RP-HPLC, and 
successively characterized by LC-ESIMS (Figure 43).  
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Figure 43 LC-ESI MS of H-G-(tL-dab)12K-NH2 oligomer. 
 
A t12 aegPNA (6, Table 1) was synthesised as reference oligomer for the binding studies. The 
synthesis of 6 was realized on the automatic synthesizer showed in Figure 13 using standard 2 µmol 
scale protocol and the commercial PNA monomers (Figure 14). Overall yield of  6 was only of 18 
% probably for aggregation problems concerning the homothymine sequence and enhanced by the 
automatic flow through synthesis. Furthermore, other two dodecamer (7 and 8, Table 1), both 
carrying a single  tL-dab unit at N-terminal and central position of the aegPNA chain, respectively, 
were synthesized in order to explore the influence of the new DABA-based monomer on the 
aegPNA binding ability. These oligomers were assembled on automatic synthesizer using a 
standard 2 µmol-scale protocol for the aegPNA part and with manual single insertion of tL-dab 
monomer using the protocol described for 5. The overall yields of 7 and 8 were 18% and 19%, 
respectively. After deprotection and detachment from the solid support with TFA, oligomer 6-8 
were purified by RP-HPLC and characterized by LC-ESIMS. 
All the dodecamers, 5-8, were quantified by UV spectroscopy, measuring the 260 nm absorbance at 
85 °C, due to the tendency of PNA to aggregate at room temperature, and calculating the overall  
extinction coefficient (ε260) as the sum of the ε260 of the PNA thymine monomer. 
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For each oligomer the CD spectrum was registered. As expected, a solution of the aegPNA 6 didn’t 
show a significant CD spectrum. In contrast, CD  spectrum of the oligomer H-G-(tL-dab)12K-NH2, 
due to its chiral nature, showed CD signal. In particular, a negative band in the 260-290 nm region 
was detected (Figure 44a) analogously to the spectrum reported in literature for the PNA analogue 
based on the L-ornithine, H-(tL-orn)10K-NH2, that presents a negative band in the same region 
(Figure 44b). The chiral tL-dab unit in 7 and 8 seemed to be not sufficient to these oligomers to show 
a significant CD signal. 
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Figura 44: (a) CD spectrum of oligomer 5 H-G-(tL-dab)12K-NH2 (4 µM) in 10 mM, phosphate buffer 
pH 7.5; (b) CD spectra of oligomers H-(tL-orn)10K-NH2 (L, 10 µM) e H-(tD-orn)10K-NH2 (D, 10 µM)  
in 10 mM phosphate buffer, 100 mM NaCl, 0.1M EDTA, pH 7. 
 
Successively, the ability of the new oligomer (tL-dab)12 to bind natural nucleic acids was evaluated by 
CD experiments, using a tandem cell, constituted from two separated reservoir communicating just 
by the upper part of the cell, in which  two solutions, initially separated, come in contact only after 
mixing by turning upside down the cell (Figura 45). 
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Figure 45 Hellma tandem cell. 
 
Initially, we considered a DNA strand complementary to the PNA dodecamers (dA12): a solution of 
dA12 in phosphate buffer was kept in one of the tandem cell reservoir (1 mL), while oligomer 5, in 
the same buffer conditions, was in the other one. CD spectrum from 200 to 320 nm, corresponding 
to the “sum” spectrum of the separated strands, was registered. Successively the cell was turned 
upside down to allow the mixing of the two samples and again a CD spectrum was recorded. As 
shown in Figure 46a,  since the “sum” and “mix” CD spectra were almost the same, no binding 
evidence was revealed, even recording CD spectra of the “mix” sample at different time (10 min, 30 
min, 1 h, 2 h, 3 h, 24 h), performing a kinetic experiment. Furthermore, also adding one equivalent 
more of oligomer 5, in a 2:1 total ratio of (tL-dab)12/dA12, in order to verify the possibility to form a 
triple helix complex, the binding was not detected. 
As positive reference, the aforementioned CD experiment was also performed between  the 
aegPNA 6 and dA12, obtaining the spectra reported in Figure 46b: in this case a clear evidence of 
the binding was detected. 
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Figura 46: Sum (red) and Mix (blue) CD spectra of (a)  (tL-Dab)12 6/dA12 H-G-(tL-dab)12K-NH2 4 µM 
and dA12 4µM in 10 mM phosphate buffer of (b) t12 PNA 7/dA12.  
 
Furthermore, also from UV melting experiment on the solution of 5 and dA12, correctly annealed, 
no binding was revealed, as shown in Figure 47: the melting curve of H-G-(tL-dab)12-K-NH2/dA12 
was a drift (red line). 
In order to study the effect of the single dabPNA insertion on the ability of aegPNA strands to bind 
complementary DNA, UV melting experiments on annealed samples containing dA12 and, 
respectively, oligomers 6, 7 and 8, were performed. Overlapped melting curves are shown in Figure 
47 and the corresponding Tm values are summarized in Table 1. From the melting data it was clear 
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that the insertion of tL-dab monomer in the middle (oligomer 8) or at N terminus (oligomer 7) of the 
homothymine aegPNA chain leads to a decreased binding efficiency to the target DNA in 
comparison to aegPNA 6. 
 
Sequences 
Tm (°C) 
± 0.5 
 H-G-(tL-dab)12-K-NH2/dA12                                                           (5)  - 
 H-G-t12-K-NH2/dA12                                                                    (6) 86.2 
 H-G-tL-dabt11-K-NH2/dA12                                                             (7) 84.8 
 H-G-t6tL-dabt5-K-NH2/dA12                                                           (8) 72.0 
 
Table 1 Homo thymine sequences synthetized. 
 
 
Figure 47  Melting curves of (5) H-G-(tL-dab)12-K-NH2/dA12, (6) H-G-t12-K-NH2/dA12, (7) H-G-tL-
dabt11-K-NH2/dA12, (8) H-G-t6tL-dabt5-K-NH2/dA12 
 
In addition, the ability of the H-G-(tL-dab)12K-NH2 oligomer to hybridise a complementary strand of 
RNA (A12) was explored. Even in this case, from the binding experiment with the tandem cell 
(Figura 48a), as well as from the kinetic CD experiment, no binding evidence was revealed. 
As reference, the same experiment on the RNA A12 was performed with the aegPNA strand (6) and, 
as expected, in this case the “sum” and “mix  CD spectra resulted different, clear evidence of 
binding (Figura 48 b). 
On the basis of these findings we concluded  that L-dabPNAs based oligomers were not able to 
bind natural nucleic acids. 
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Figure 48 sum (red) and Mix (blue) CD spectra of (a) H-G-(tL-dab)12K-NH2 4 µM and A12 RNA 
4µM in 10 mM phosphate buffer and (b) t12 7/A12. 
 
2.2 Synthesis and oligomerization of tD-dab monomer, and binding studies on (tD-dab)6 oligomer 
 
Since the PNA oligomer based on L-DABA don’t bind natural nucleic acids and considering that  
different stereoisomers have different ability to adopt the conformation required to bind DNA or 
RNA, we thus explore the hybridization of the D-DABA-based nucleopeptides to nucleic acid 
targets. Nevertheless,  in this way we continue our investigation on  the hypothized prebiotic role of 
dabPNAs, after the recovery of  both L and D-DABA enantiomers in meteoritic soil.57 Our interest 
was successively devoted to the realization of the enantiomeric tD-dab monomer, starting from the 
commercial Boc-(D)-DAB(Fmoc)-OH (Scheme 4).  
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Scheme 4 Synthesis of tD-dab monomer. 
 
The tD-dab monomer 9, purified by RP-HPLC and characterized by NMR and LC-ESI MS, was 
oligomerized manually on solid phase (Scheme 5) to the corresponding H-G-(tD-dab)6K-NH2  (10) 
following the same synthetic procedure used for the obtainment of oligomer 5.  
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Scheme 5 Synthesis of H-G-(tD-dab)6K-NH2 oligomer. 
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After cleavage and deprotection, homopolymer 10 was purified by semipreparative RP-HPLC on a 
C18 column, and successively characterized by LC-ESIMS (Figure 49). 
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Figure 49 LC-ESIMS of H-G-(tD-dab)6K-NH2 homopolymer . 
 
CD spectrum of single strand H-G-(tD-dab)6K-NH2 (10), depicted in Figure 50a (blu line), showed a 
mirror image relationship relative to the enantiomer H-G-(tL-dab)12K-NH2  5 (red line, Figure 50a), in 
analogy to the CD spectra reported in literature by Sforza et al.61 for the L- and D-ornPNAs H-
(torn)10K-NH2, showed in Figure 50b. 
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Figure 50 a) Mirror-image relationship between H-G-(tL-dab)12-K-NH2 (red line) and H-G-(tD-dab)6K-
NH2 (blu line), 4 uM, 10 mM Pi, 10 °C; b) H-(tL-orn)10K-NH2 (L, 10 µM) e H-(tD-orn)10K-NH2 (D, 10 
µM)  in 10 mM phosphate, 100 mM NaCl, 0.1M EDTA, pH 7.  
 
Furthermore, we performed CD experiments to verify the ability of H-G-(tD-dab)6K-NH2 to bind 
DNA and RNA (dA12/A12) using the “tandem cell”. No difference between the sum CD spectrum, 
obtained before mixing the two components, and the complex CD spectrum, recorded after the 
mixing, was revealed for oligomer 10  with both DNA and RNA. The CD spectra remained almost 
the same also at different times by performing kinetic CD studies, or adding another equivalent of 
H-G-(tD-dab)6K-NH2 to the solution obtaining a 2:1  final ratio of (tD-dab)6/dA12 to verify the 
possibility to form triple helix. In addition UV thermal experiments of the annealed mixture  
confirmed the absence of any significant H-G-(tD-dab)6K-NH2 /DNA(RNA) interaction, showing 
little drift curves. 
 
2.3 Syntheses and oligomerization of aL-dab and aD-dab monomers, and binding studies 
 
Since dabPNAs based on L- and D-DABA don’t bind natural nucleic acids, we explored the 
possibility that complementary nucleopeptides based on D or L-DABA could bind between 
themselves. This property would be interesting in order to develop novel DABA-based dendrimeric 
systems, as new materials, and also to realize new diagnostic tools, as for example new molecular 
beacon probe. In particular, in the case of the molecular beacon, it would be very interesting if the 
stem portion of this kind of probe don’t recognize natural targets (Figure 51), increasing the 
specificity of the system. 
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Figure 51 Molecular beacon with dabPNA-based stem. 
 
To verify this interesting possibility, homoadenine and homothymine hexamers based on L- and D-
DABA were realized in order to find, if possible, the correct combination of chirality suitable for 
obtaining the binding. In particular, we obtained and studied the following systems: 
H-G-(aL-dab)6K-NH2  / H-G-(tL-dab)6K-NH2; H-G-(aL-dab)6K-NH2  / H-G-(tD-dab)6K-NH2; 
H-G-(aL-dab)6K-NH2/H-G-(tL-dab-tD-dab)3K-NH2; H-G-(aL-dab-aD-dab)3K-NH2/H-G-(tL-dab-tD-dab)3K-NH2. 
With the previously synthesized tL-dab and tD-dab monomers, we initially realized the sequences H-G-
(tL-dab)6K-NH2 (11) and H-G-(tL-dab-tD-dab)3K-NH2 (12), following the same synthetic procedure for 
5. 
In order to assemble the poliadenine sequences, the new aL-dab and aD-dab monomers were 
synthesized, by reacting L and D-Boc-DAB(Fmoc)-OH (1 and 1’), respectively, with  Bhoc-
protected carboxy methylated adenine. (Scheme 6). 
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Scheme 6 Syntheses of aL-dab / aD-dab monomers. 
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The Fmoc-protected monomers (13 and 13’) synthesized, 
 
were purified by RP-HPLC without TFA 
in the eluents, to avoid the loss of the acid labile Bhoc protecting group. aL-dab and aD-dab were 
characterized by 1H /13C NMR and LC-ESI MS (Figure 52). 
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Figure 52 LC-ESI MS profile of aL-dab monomer. 
 
The new chiral monomers aL-dab and aD-dab were used to synthetize H-G-(aL-dab)6K-NH2 14, and H-G-
(aL-dab-aD-dab)3K-NH2 15, with alternate chirality, following the same manual synthetic protocol used 
for all the previous syntheses to minimize racemization problems.  
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Scheme 7 Syntheses of polyadenine DABA-based oligomers. 
 
The coupling efficiency for the synthesis of 14 and 15, checked by UV Fmoc test, was on average 
around 70% in the first five synthetic steps and decreased rapidly in the last ones, giving an overall 
yields of 16% (14) and 18% (15). 
After cleavage and deprotection, the oligomers were purified by semipreparative RP-HPLC, and 
successively characterized by LC-ESIMS, which confirmed the identity of the products. The LC-
ESIMS profile of the new oligomer 14 is reported in Figure 53 as an example. 
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Figure 53 LC-ESI MS of H-G-(aL-dab)6K-NH2. 
 
Oligomer 14, due to its chiral nature, showed CD signal, as evidenced by its CD spectrum reported 
in Figure 54a (blue line). CD experiments revealed that the spectrum of (aL-dab)6 showed the same 
trend as that of homo polymer having  the same chirality (tL-dab)12 (red line, Figure 54b), with a band 
shift of the minimum between 250-300 nm from 276 nm of (tL-dab)12 to 266 nm. 
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Figure 54 a) Overlapped CD spectra of (aL-dab)6 (blue line)and (tL-dab)12 (red line), 8 µM in 10 mM 
phosphate buffer, pH 7.5; b)  Overlapped CD spectra of (aL-dab-aD-dab)3 (blue line) and (tL-dab-tD-dab)3 
(red line), 4 µM in 10 mM phosphate buffer, pH 7.5.
 
 
In addition, by comparing the CD spectra of the alternate oligomers (aL-dab- aD-dab)3 and (tL-dab- tD-
dab)3, a positive band between 260-320 nm was revealed, with the maxima centred at 274 nm, in the 
case of (tL-dab- tD-dab)3, and at 284 nm, in the case of  (aL-dab-aD-dab)3 (Figure 54b). 
CD hybridization studies were performed with tandem cell on H-G-(aL-dab)6K-NH2 /(tL-dab)6: no 
significant binding evidence was revealed in this case. Indeed only little changes are recorded for 
the sum and mix spectra relative to this complex (Figure 55). 
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Figure 55 Red sum and blue mix of (aL-dab)6/ (tL-dab)6 (4 µM in 10 mM phosphate buffer, pH 7.5). 
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Other CD experiments were carried out on the following systems: (aL-dab)6/ (tD-dab)6, (aL-dab)6/(tL-dab-
tD-dab)3 and (aL-dab- aD-dab)3/(tL-dab- tD-dab)3. In the first case, no binding evidence was revealed, while 
in the second one, a little difference between the sum spectra (red line) and the mix (blue line) was 
observed (Figure 56), suggesting a possible hybridization between the strand with alternate chirality 
and homochiral oligomer. However, this finding was not supported by the UV melting experiment 
on the annealed strands: drift curve was recorded (data not shown).  
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Figure 56 Red sum and blue mix of (aL-dab)6/(tL-dab-tD-dab)3 (4 µM in 10 mM phosphate buffer, pH 
7.5). 
 
In the case of (aL-dab- aD-dab)3/(tL-dab-tD-dab)3, CD measurements with tandem cell revealed a 
difference between the sum and mix spectra (Figure 57), which, in this case, was confirmed also by 
the UV thermal denaturation curve (Figure 58): indeed, a transition phase at 11 °C was detected. 
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Nevertheless we plan to perform a large scale synthesis of the strands involved in this experiment, 
in order to evaluate the stability of the system in function of the concentration of the two strands 
and to obtain a CD titration curve, useful to establish the stoichiometry of the formed complex. 
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Figure 58  UV melting of  (aL-dab- aD-dab)3/(tL-dab-tD-dab)3. 
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2.4 Conclusion  
 
In our research for the development of new ODN-like drugs or diagnostics, we designed and 
realized chiral nucleo-γ-peptides, dabPNAs, isomer of the aegPNAs and characterized by a 2,4-
diaminobutyric acid (DABA)-based backbone carrying the carboxymethylated nucleobase on its α 
amino group. Our interest to dabPNAs arises, besides from the obtainment of new molecules for 
potential therapeutic and diagnostic applications, also from their involvement in the prebiotic world, 
as recently proposed by Meierhenrich et al. 57 This proposal followed the recovery of DABA in the 
extraterrestrial soil of the Murchison meteorite together with the molecular DNA constituent purine 
and pyrimidine bases, and other diaminoacids.57,58 In order to realize the chiral dabPNA oligomers, 
the new monomers tL-dab, tD-dab, aL-dab and aD-dab  were synthesized in good yield using suitable 
protected building blocks and characterized by NMR and ESI-MS techniques. 
Initially, the homothymine oligomers (tL-dab)12 and (tD-dab)6 were synthesized using a synthetic 
strategy that ensured the maintenance of chirality during the coupling steps, and tested for 
hybridization towards natural nucleic acids. No binding evidence with both DNA (dA12) and RNA 
(A12) was revealed by CD and UV experiments. 
Furthermore, the insertion of a single tL-dab unit in the middle or at N terminus of a homothymine 
aegPNA chain leads to a decreased binding efficiency to the target DNA in comparison to full 
aegPNA. 
Since dabPNAs based on L- and D-DABA don’t bind natural nucleic acids, we explored the 
possibility that complementary nucleopeptides based on D or L-DABA could bind between 
themselves. This property would be interesting in order to develop novel DABA-based dendrimeric 
systems, as new materials, and also to realize new diagnostic tools, as for example new molecular 
beacon probes. To verify this interesting possibility, aL-dab and aD-dab monomers were oligomerized 
to the homoadenine hexamers (aL-dab)6 and (aL-dab- aD-dab)3. In order to find the correct combination 
of chirality suitable for obtaining the binding also the oligomer (tL-dab-tD-dab)3 was realized, to 
perform the hybridization studies. From CD and UV experiments, binding evidence was revealed in 
the case of the complementary oligomers with alternate chirality, (aL-dab-aD-dab)3 and (tL-dab-tD-dab)3 
even if the stability of the complex formed was not so high (Tm=11°C). However further 
experiments to better establish the stability and stoichiometry of this hybrid are required. 
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2.5 Materials and methods 
 
Chemicals 
Fmoc-Gly-OH, HATU, Fmoc-Lys(Boc)-OH, PyBOP were purchased from Novabiochem. 
Anhydroscan DMF and NMP were from LabScan. Piperidine was from Biosolve. Solvents for 
HPLC chromatography and acetic anhydride were from Reidel-de Haën. TFA, Rink-amide resin, 
TCH2COOH, acetic acid were Fluka. [N6-(benzhydryloxycarbonyl)-adenine-9-yl] was purchased 
from ASM Research Chemicals GmbH & Co. Perspective Biosystem PNA kit (Fmoc/Bhoc 
monomers, HATU activator, Base solution, Wash B, DIEA, Cap Solution, Deblock solution) was 
purchased from PRIMM (Milan, Italy). Boc-DAB(Fmoc)-OH is from Bachem. DCM and TFA (for 
HPLC) were from Romil. Deuterated solvents (DMSO, methanol) were from Aldrich. Thin-layer 
chromatography (TLC) analyses were performed on silica gel Macherey-Nagel G-25 UV254 plates 
(0.25 mm thick) visualised by UV light and by a ninhydrin staining solution. The reactions were 
monitored by TLC until all starting material had been consumed. Solvents for TLC analyses and 
diethyl ether were from Carlo Erba, dA12 was purchased from Biomers (Ulm, Germany).  
 
Apparatus 
 
1H NMR and 13C NMR spectra were recorded at 25 °C on Varian unity 300 MHz and Varian Inova 
600 MHz spectrometers. Chemical shifts (δ) are given in parts per million (ppm) and all coupling 
constants (J) in Hz. Proton chemical shifts were referenced to residual CHD2SOCD3 (δ=2.49, quin) 
and CHD2OD (δ=3.30, quin) signals. 13C NMR chemical shifts were referenced to the solvent 
(CD3SOCD3: δ=39.5, sept; CD3OD: δ=49.0, sept). 
 
aegPNA oligomers were assembled on solid-phase with an Applied Biosystems Expedite 8909 
oligosynthesizer. 
 
Crude samples containing PNA oligomers were centrifuged for 4 min at 4000 rpm (Z 200 A, 
Hermle). 
 
Products were analysed by LC-MS, performed on an MSQ mass spectrometer (ThermoElectron, 
Milan, Italy) equipped with an ESI source operating at 3 kV needle voltage and 320 °C, and with a 
complete Surveyor HPLC system, comprising an MS pump, an autosampler, and a PDA detector, 
by using a Phenomenex Jupiter C18 300 Å (5 µm, 4.6×150 mm) column. Gradient elution was 
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performed at 40 °C (monitoring at 260 nm) by building up a gradient starting with buffer A (0.05% 
TFA in water) and applying buffer B (0.05% TFA in acetonitrile) with a flow rate of 0.8 ml/min. 
Semi-preparative purifications were performed by RP-HPLC on a Shimadzu LC-8A, equipped with 
an SPD-10A VP UV/Vis detector, and on a Hewlett Packard/Agilent 1100 series, equipped with a 
diode array detector, by using a Phenomenex Juppiter C18 300 Å (10 µm, 10×250 mm) column. 
Gradient elution was performed at 45 °C (monitoring at 260 nm) by building up a gradient starting 
with buffer A (0.1% TFA in water) and applying buffer B (0.1% TFA in acetonitrile) with a flow 
rate of 4 ml/min. 
Samples containing PNAs (crude or purified), were lyophilized in a FD4 Freeze Dryer (Heto Lab 
Equipment) for 16 hours. 
Circular dichroism (CD) spectra were obtained at 20 °C on a Jasco J-810 spectropolarimeter using 
1-cm quartz cuvette (Hellma). 
Ultraviolet (UV) spectra and UV melting experiments were recorded on a UV-Vis Jasco model V-
550 spectrophotometer equipped with a Peltier ETC-505T temperature controller using 1-cm quartz 
cuvette (Hellma). 
 
Synthesis of the (D, L) t-dabPNA monomer 
Nγ-Fmoc-L-2,4-diaminobutyric acid, (1 or 1’) (Scheme 2). Commercial Fmoc/Boc-protected 2,4-
diaminobutyric acid (L and D) 1 (200 mg, 0.45 mmol) was treated with a solution of 
TFA/DCM/H2O 4.5:4.5:1 (8 ml) at 50 °C. After stirring for 1 h, the pH of the solution was adjusted 
to 5 by dropwise addition of 1 M aqueous KOH. The obtained white precipitate was filtered, 
washed with DCM and coevaporated three times with dry CH3CN (138 mg of 2, 0.40 mmol, 90% 
yield). The crude precipitate contained prevalently one product, as evidenced by TLC, which 
showed only one spot at Rf= 0.14 (6:4 CH2Cl2/CH3OH), and by LC-MS. ESI-MS m/z: 340.4 
(found), 341.38 (expected for MH+);  δH (300 MHz, DMSO-d6) 8.27 (3H, br s, NH3+), 7.29-7.89 
(9H, aromatic CH Fmoc and Fmoc-NH), 4.32 (2H, m, FmocCH-CH2), 4.22 (1H, m, FmocCH-CH2), 
3.90 (1H, m, CHα), 3.14 (2H, m, CH2NH), 1.92 (2 H, m, CH2CHα). 
 
Nγ-Fmoc-Nα-(thymin-1-ylacetyl)-2,4-diaminobutyric acid (L and D) 4,9 (Scheme 2,4 ). Product 
2 or 2’ (1 eq, 138 mg, 0.40 mmol) was dissolved in dry DMF (6 ml) and 0.6 eq of DIEA (41µL) and 
TMP (32.4 µL)  reacted with TCH2COOH (149 mg , 0.81 mmol, 2 eq), HATU (293 mg, 0.77 
mmol, 1.9 eq), DIEA (137 µL, 0.8 mmol, 2 eq) and TMP (108 µL, 0.8 mmol, 2 eq,) which were 
previously preactivated for 2 min before adding to product 2 (or 2’). 
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After 2 h the reaction was quenched by adding 60 ml of water, the crude was frozen to -80°C and 
lyophilized. The crude material obtained was purified by semipreparative HPLC on Shimadzu 
instrument using increasing amounts (15-70% in 25 min) of solution B in A, giving pure sample 4,9 
(148 mg, 0.29 mmol, 72% yield) as a white powder; Rf= 0.50 (8:1:1 butanol:acetic acid:water); 
LCESI-MS (Figure 2) m/z: 507.00 (found), 507.52 (expected for MH+); δH (600 MHz, DMSO-d6) 
11.35 (1H, br s, NH thymine), 8.54 (1H, br s, NH amide), 7.98 (2H, d, J=7.3, aromatic CH Fmoc), 
7.77 (2H, d, J=7.3, aromatic CH Fmoc), 7.51 (2H, t, J=7.3, aromatic CH Fmoc), 7.49-7.51 (1H, m, 
Fmoc-NH), 7.42 (2H, t, J=7.3, aromatic CH Fmoc), 7.41 (1H, s, CH thymine), 4.43 (2H, s, CH2 
acetyl linker), 4.05-4.50 (4H, m, FmocCH-CH2 and CHα), 3.14 (2H, m, CH2NH), 2.00 (1H, m, part 
of an AB system centred at 1.91, CH2CHα), 1.83 (1H, m, part of an AB system centred at 1.91, 
CH2CHα), 1.82 (3H, s, CH3 thymine);  δH (600 MHz, CD3OD) 7.78 (2H, d, J=7.3, aromatic CH 
Fmoc), 7.64 (2H, d, J=7.3, aromatic CH Fmoc), 7.38 (2H, t, J=7.3, aromatic CH Fmoc), 7.36 (1H, s, 
CH thymine), 7.30 (2H, t, J=7.3, aromatic CH Fmoc), 4.47 (2H, s, CH2 acetyl linker), 4.19-4.50 
(4H, m, FmocCH-CH2 and CHα), 3.19 (1H, m, part of an AB system centred at 3.22, CH2NH), 3.25 
(1H, m, part of an AB system centred at 3.22, CH2NH), 2.11 (1H, m, part of an AB system centred 
at 1.98, CH2CHα), 1.85 (1H, m, part of an AB system centred at 1.98, CH2CHα), 1.84 (3H, s, CH3 
thymine); δC (150 MHz, DMSO-d6) 170.98 (COOH), 168.48 (CH2CONH), 160.10 (thymine C-4), 
155.00 (OCONH), 147.96 (aromatic Fmoc 2C), 147.89 (thymine C-2), 146.36 (aromatic Fmoc 2C), 
144.73 (thymine C-6), 131.65 (aromatic Fmoc 2CH), 131.11 (aromatic Fmoc 2CH), 129.18 
(aromatic Fmoc 2CH), 124.15 (aromatic Fmoc 2CH), 111.96 (thymine C-5), 69.40 (Fmoc CH2), 
53.02 (CH2 acetyl linker), 50.73 (CHα), 44.1 (Fmoc CH), 41.30 (CH2NH), 22.56 (CH2CHα), 15.91 
(thymine CH3). 
 
aL-dab and aL-dab (13 and 13’) 
The monomers 13 and 13’ were synthesised starting from N6-(benzhydryloxycarbonyl)-adenine-9-
yl-acetic acid and from Boc-(S)-DAB(Fmoc)-OH and Boc-(D)-DAB(Fmoc)-OH diaminoacids, the 
same synthetic strategy used in the case of products 4 and 9. The monomers were purified by RP-
HPLC and characterized by LC-ESIMS and NMR. 
 
Solid phase synthesis of oligomers (5-15)  
 
Solid support functionalization and manual solid-phase oligomerizations were carried out in short 
PP columns (4 ml) equipped with a PTFE filter, a stopcock and a cap. Solid support 
functionalization: Rink-amide resin (0.50 mmol NH2/g, 128 mg) was functionalized with a lysine 
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(Fmoc-Lys(Boc)-OH, 0.5 eq, 14.8 mg, 32 µmol) using PyBOP (0.5 eq, 16.8 mg, 32 µmol) as 
activating agent and DIEA (1 eq, 12 µL, 64 µmol) as base for 30 min at room temperature. Capping 
of the unreacted amino groups was performed with Ac2O (20%)/ DIEA (5%) in DMF. Loading of 
the resin was checked by measuring the absorbance of the released Fmoc group (ε301=7800, 
quantitative yield) after treatment with a solution of piperidine (30%) in DMF (UV Fmoc test) and 
resulted reduced to 0.25 mmol/g respect to the initial functionalization. Automatic solid-phase 
assembly of the aegPNAs was performed on an Expedite 8909 Nucleic Acid Synthesis System 
using a standard 2 µmol-scale protocol and Fmoc chemistry leaving the final Fmoc on in order to 
evaluate SPS yields by UV Fmoc test. Manual couplings of dabPNA monomers were monitored by 
UV Fmoc test in order to evaluate the incorporation yields of the new monomer. A glycine residue 
(3 eq) was attached to the N-terminus of all the oligomers by using PyBOP (3 eq)/DIEA (6 eq) as 
activating system in DMF. After removal and quantification of the Fmoc group, all oligomers were 
cleaved from the resin and deprotected under acidic conditions (TFA/m-cresol 4:1 v/v). The 
oligomers were isolated by precipitation with cold diethyl ether, centrifugation and lyophilization. 
Purified oligomers (semipreparative HPLC) were quantified and characterised by LC-ESIMS. 
 
H-G-(tL-dab)12-Lys-NH2 (5) was assembled manually on Rink-amide-Lys-NH2 resin (32 mg, 8 µmol 
0.25 mmol/g,) using the following protocol: the monomer 4 Fmoc-tL-dab-OH (120 µl, 24 µmol, 3 
eq), and the coupling agent HATU (120 µl, 24 µmol, 3 eq), were dissolved in 100 µL of DMF and 
stored at rt for 5 min; then it was introduced into the reactor. Immediately 1/4 (30 µL) of the total 
amount of a base solution (120 µl, 24 µmol, 3 eq, TMP 0.2 M) was  added to start the reaction, and 
the reaction mixture was stirred. The other three amount of the base (1/4) portions were added one 
every 15 minutes, and the coupling was left for 1h with shaking at room temperature. 
Successively, unreacted amino groups were capped with PNA Cap solution for 5 min. Fmoc 
removal was accomplished with PNA Deblock solution (5 min) and was monitored for every step 
by UV measurements: average yield for the first six steps was 96% while for the last six steps a 
lowering of the yields from 96 to 70% was observed probably because of the enhanced aggregation 
tendency of the increasing homothymine chain (overall yield: 25%). Yield of the last coupling with 
glycine resulted to be of 97%. After cleavage and deprotection, the oligomer 5 was purified by 
semipreparative RP-HPLC using a linear gradient of 8% (for 5 min) to 25% B in A over 30 min: 
tR=31.0 min; UV quantification of the purified product gave 100 nmol of 5; ESI-MS (Figure 3) m/z: 
1134.8 (found), 1133.4 (expected for [M+3H]3+). 
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H-G-t12-K-NH2 (6) Standard t12 aegPNA was assembled on Rink-amide-Lys-NH2 resin (32 mg 
,0.25 mmol/g) on automatic synthesizer. After the synthesis was complete the final Fmoc was left 
on and removed manually to perform Fmoc UV test. The overall yield of t12 was of only 18% 
probably because the flow through synthesis of automatic synthesizer enhances the aggregation 
problems of the homothymine sequence. Glycine was incorporated manually as last residue with 
high efficiency (98% yield). The cleaved and deprotected oligomer was purified by semipreparative 
HP HPLC using a linear gradient of 8% (for 5 min) to 20% B in A over 30 min: tR=27.9 min; UV 
quantification of the purified product gave 60 nmol of 6; ESI-MS m/z: 1132.0 (found), 1697.1 
(found), 1133.4 (expected for [M+3H]3+), 1699.7 (expected for [M+2H]2+). 
 
H-G-tdabt11-K-NH2 (7) The aegPNA part of 8 was assembled on Rink-amide-Lys-NH2 resin (0.25 
mmol/g, 32 mg) by automatic synthesizer leaving the final Fmoc on (yield: 20%), while the tL-dab 
monomer was attached manually as last residue following the protocol described for 5 (yield: 95%). 
After last coupling with glycine, an overall yield of 18 % was obtained. After cleavage and 
deprotection, the oligomer was purified by semipreparative HP HPLC using a linear gradient of 8% 
(for 5 min) to 17% B in A over 35 min: tR=29.8 min; UV quantification of the purified product gave 
70 nmol of 7; ESI-MS m/z: 1133.0 (found), 1133.4 (expected for [M+3H]3+), 1699.8 (found), 
1699.7 (expected for [M+2H]2+). 
 
H-G-t6tdabt5-K-NH2 (8) The synthesis of the aegPNA part of 8 was performed on Rink-amide-Lys-
NH2 resin (0.25 mmol/g, 32 mg) by automatic synthesizer except for the dabPNA monomer which 
was attached manually in the middle of the aegPNA sequence (overall yield: 20%). Glycine was 
incorporated manually as last residue with a 95% yield. The cleaved and deprotected oligomer was 
purified by semipreparative HP HPLC using a linear gradient of 7% (for 5 min) to 19% B in A over 
40 min: tR=30.1 min; UV quantification of the purified product gave 80 nmol of 8; ESI-MS m/z: 
1132.8 (found), 1133.4 (expected for [M+3H]3+), 1698.5 (found), 1699.7 (expected for [M+2H]2+). 
 
Oligomers 10, 11, 12, 14, 15 were assembled manually on Rink-amide-K-NH2 resin (8 mg, 2 µmol, 
0.25 mmol/g) using the same synthetic procedure as described for oligomer 5. 
 
H-G-(tD-dab)6K-NH2 (10) Purified by HP HPLC using a linear gradient of 5% (for 5 min) to 22 % B 
in A over 25 min: tR=25 min; UV quantification of the purified product gave 120 nmol; ESI-MS 
m/z: 900.07 (found), 900.8 (expected for [M+2H]2+). 
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H-G-(tL-dab)6K-NH2 (11) Purified by HP HPLC using a linear gradient of 5% (for 5 min) to 22 % B 
in A over 25 min: tR=25 min; UV quantification of the purified product gave 110 nmol; ESI-MS 
m/z: 900.08 (found), 900.8 (expected for [M+2H]2+). 
 
H-G-(tL-dab-tD-dab)3K-NH2 (12) Purified by HP HPLC using a linear gradient of 5% (for 5 min) to 
25 % B in A over 25 min: tR=23 min; UV quantification of the purified product gave 95 nmol; ESI-
MS m/z: 900.3 (found), 900.8 (expected for [M+2H]2+). 
 
H-G-(aL-dab)6K-NH2 (14) Purified by HP HPLC using a linear gradient of 4% (for 5 min) to 25 % B 
in A over 25 min: tR=18.4 min; UV quantification of the purified product gave 101 nmol; ESI-MS 
m/z: 927.9 (found), 927.08 (expected for [M+2H]2+). 
 
H-G-(aL-dab-aD-dab)3K-NH2 (15) Purified by HP HPLC using a linear gradient of 5% (for 5 min) to 
25 % B in A over 25 min: tR=22 min; UV quantification of the purified product gave 130 nmol; 
ESI-MS m/z: 900.07 (found), 927.08 (expected for [M+2H]2+). 
 
UV and CD studies 
Purified oligomers were dissolved in a known amount of milliQ water and quantified by UV 
measurements (T=85 °C, absorbance value at λ=260 nm). The epsilon used for the quantification of 
the oligomers t12(103.2 mM-1), t6 (51.6 mM-1), a6 (82.2 mM-1) were calculated using the molar 
extinction coefficient of thymine (8.6 mM-1) and adenine (13.7 mM-1) of  aegPNA monomers. 
 Annealing of all PNA oligomers with complementary strands was performed by mixing equimolar 
amounts of the two components in 10 mM phosphate buffer at pH 7.5 to achieve duplex 
concentration of 4 µM. The solution was heated at 85 °C (5 min) and then allowed to cool slowly to 
room temperature. 
Thermal melting curves (Figure 4) were obtained by recording the UV absorbance at 260 nm while 
the temperature was ramped from 20 to 97 °C at a rate of 0.5°C/min. Tm values, calculated by the 
first derivative method, were reported in Table 1. 
CD spectra were recorded from 320 to 200 nm at 20°C: scan speed 50 nm/min, data pitch 2 nm, 
band width 2 nm, response 4 sec, 3 accumulations.
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PART 3: Non enzymatic method for SNP (single nucleotide polymorphism) 
analysis. 
 
This project was carried out during a period of the third year of Phd at University of Edinburgh 
(School of Chemistry) in the laboratory of Prof. M. Bradley and involved a project entitled "Non 
enzymathic method for SNP (single nucleotide polymorphism) analysis ". 
Single Nucleotide Polymorphism (SNP) refers to single base alterations which occur within the 
human genome giving rise to structure and functional protein modifications. SNPs, it is thought to 
be responsible of various diseases and its finding would help to predict hereditary diseases and the 
possibility of prophylactic treatments. Therefore high-throughput methods which were cost-efficient 
are highly required. Recently, The International HapMap Consortium genotyped more than 1 
million in 269 individuals of SNPs62 which can give an idea of the importance of the issue. Current 
methods for realizing SNPs analysis are enzymatic-based relying in the recognition by enzymes of 
allele differences. Examples of these methods are the restriction fragment length polymorphism 
(SNP-RFLP) 63 which use restriction enzymes and extension reactions with the use of polymerases 
and fluorescence modified nucleotides. If an allele contains a recognition site for a restriction 
enzyme and another not, digestion of the two alleles generate two fragments of different sizes. 
Other methods involve the use of microarrays with include specific markers for SNPs.  
In reality today SNPs are designed primarily through microarrays, which allow the simultaneous 
analysis of hundreds of different SNPs and a quick analysis prepared by a computer, but in both 
cases it requires the use of specific marker enzyme. 
 
                                                 
 
Figure 1 Example of   polymorphism C/T = bp C/G substituted by bp T/A 
 72 
3.1 Labelling method for molecules and nucleobases. 
 
The aim of this project was to synthesize and characterize new  fluorescently labelled nucleosides, 
to use as building blocks and primers for non enzymatic SNP analysis, chemically based. 
Each nucleoside would be labelled with different fluorophores (FAM, TAMRA, Texas Red, Cy5) as 
shown as example in the following scheme. 
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Scheme 1 Synthesis of novel fluorescently labelled nucleosides. 
 
Fluorescence labelling of biologically active compounds is a technique for preparing biochemical 
probes for in vivo and in vitro studies. Conventional labelling methods rely upon reaction of amine 
or thiol with activated dyes, conditions under which side products may form. 
In most cases, it is necessary to isolate the desired product from unreacted reagents and side 
products. The preparation of activated dye, moreover, can be difficult given their sensitivity to 
moisture and various nucleophiles. Thus, a procedure that allows facile preparation of the activated 
dye and labelling of biologically interesting compounds without chromatographic steps would be a 
useful tool. A versatile labelling method employing support bound nitrophenol active ester is 
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described. The method developed allowed the synthesis of pure fluorescently molecules using 
supported dyes on solid phase, and furthermore, allowing the solid support to be recycled several 
times. 
Nitrophenol resin (3) was synthesized by standard coupling of amino methyl polystyrene resin with 
3-hydroxi-4-nitrobenzoic acid (2). The nitrophenol resin (3) was then coupled to the carboxyl 
groups respectively of 5(6)-carboxirhodamine (Scheme 2) and of 5(6)-carboxifluorescein (Scheme 
3), with the use of DIC as coupling reagents in presence of catalytic amount of 4-
dimethylaminopyridine (DMAP), resulting in the activated ester resins (4 and 7). Upon reaction 
with amine nucleophiles in 2 different solvents, DMF and DCM, amide products (5, 9 and 10) were 
formed, and collected by simple filtration, and after rinsing of the resin and evaporation of the 
solvents, the dyes were obtained  
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Schema 2 A) DIC, HOBt (3 eq) , 3-hydroxy-4-nitrobenzoic acid (3 eq) in DMF B) resin, DIC (1 
eq) (3eq) DIEA, 5(6)-carboxirhodamine (6eq) (3 eq), DMAP catalytic amount in DMF C) 
propargylamine (0.9 eq) in DMF. 
 
The purity and identity of the products were characterized by LC/MS equipped with a diode array 
detector and an ESI mass spectrometer. In figure 2 is showed the ESI-MS (positive mode) of the 
propargylammine labelled with 5(6) carboxyrhodamine. 
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Figure 2 ESI-MS of 5(6)-carboxyrhodamine propargylamine. 
 
Activated esters (3, 4) were reacted with propargylamine (Scheme 1), 2-aminoethanethiol (Scheme 
3) and 2,2-dimetoxy ethylamine (Scheme 4), respectively. The products obtained, were pure and did 
not require further purification (90-99% pure). 
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Scheme 3 of 5(6)-carboxyfluorescein cleavage from solid support by propargylamine and 2-
aminoethanethiol. 
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Scheme 4 5(6)-carboxyfluorescein and 5(6)-carboxyrhodamine cleavage from solid support by 2,2-
dimethoxy ethylamine (0.9 eq). 
 
In figure 3 are showed the ESI-MS (positive mode) respectively of 5(6)-carboxyrhodamine and of 
5(6)-carboxyfluorescein 2,2-dimethoxy ethylamine complex, as we can notice only one peak of 
ionization was found for these compounds. 
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Figure 3 ESI-MS of products 11 and 12. 
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Once the labelling method was optimized, a propagylamine linker was synthesized. Amino 
functionality of propagylamine was protected with trifluoacetic anhydride as described in Scheme 
5. 
 
NH2 NH CF3
O
8 13
A
 
 
Scheme 5 A 1.12 eq TFAA, 2 eq TEA, CH2Cl2, 0 to rt, 1.1 M, 14 h, 74% 
 
Chromatography column on silica gel, eluted with DCM, readily furnished the desired product 13 in 
good yield (74 %), which was fully characterized by LC-ESI MS and 1H/13C NMR.  
The obtained product 2,2,2-trifluoro-N-prop-2ynyl-acetamide (13) was used to react, via classical 
Sonagashira coupling, performed with a palladium catalyst, and a copper (I) co catalyst (mechanism 
shown in Figure 4, with the 5-iodo-cytosine and 5-iodo-thymine derivatives to obtain products 15 
and 17 in good overall yield (78% and 75%). (Scheme 6). 
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Scheme 6 Cytosine/thymine 1eq, Pd[(C6H5)3P]4 10% in weight, CuI 20% mol, 5 eq Amberlite Ira-
67, 0.2 M DMF. 
 
Sonogashira coupling of aryl or vinyl halides with terminal alkynes is a transition metal-mediated 
cross coupling reactions, emerged as a powerful methods for the formation of carbon-carbon bonds. 
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The palladium complex activates the organic halides by oxidative addition into the carbon-halogen 
bond. In contrast, copper(I) halides react with the terminal alkyne and producecopper (I) acetylide, 
which acts as an activated species for the coupling reactions (Figure 4). 
 
 
 
Figure 4 Sonogashira reaction mechanism. 
 
Products 15 and 17 were deprotected (Scheme 7) in basic conditions (6 M NH3 in H2O/MeOH), 
giving the corresponding free amine. Coupling with supported dyes (4, 7), quickly formed the 
desired labelled bases which were released to the reaction media and collected by filtration. The 
purity and identity of the products 20 and 21 was revealed by ESI-MS and NMR. 
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Scheme 7 Synthesis of novel fluorescently labelled nucleosides 
 78 
3.2 Conclusion 
 
A versatile labelling method employing supported nitrophenol activated ester was developed. This 
strategy can be adopted to label biologically active amines for use as molecular probes or 
nucleosides. The method allowed the synthesis of pure labelled molecules, without further 
chromatographic purification. Furthermore, and not less important, the solid support is recyclable, 
reducing in this way the cost for the syntheses. Two active esters, (3, 4) and 3 different amines were 
tested. The obtained products were pure and did not require further purification (90-99% yield).The 
same strategy was used for nucleosides labelling allowing the synthesis of TAMRA-cytosine and 
FAM-thymine. 
Once all fluorescently labelled nucleosides will be synthesized a new non-enzymatic SNPs 
detection could be carried out using high-throughput capability of microarray technology. 
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3.3 Materials and methods 
 
Chemicals  
All commercially available reagents were used as received. Amberlite IRA-67, 10% palladium on 
charcoal, and CuI were obtained from Aldrich Chemical Company, Inc. DMF (DriSolv) was 
purchased from EMD Chemicals, Inc. Nucleoside substrates were obtained from Berry & 
Associates or Sigma. Propargylamine, 2-aminoethanethiol, 2,2-dimetoxy ethylamine and 5(6)-
carboxyfluorescein were purchased from Sigma Aldrich. Rhodamine WT was purchased from 
Abbey color. Thin-layer chromatography (TLC) was conducted with E. Merck silica gel 60 F254 
pre-coated plates, (0.25 mm) and visualized using a combination of UV, anisaldehyde, ceric 
ammonium molybdate, and potassium permanganate staining. ICN silica gel (particle size 0.032-
0.063 mm) was used for flash column chromatography. 
 
Apparatus 
1H NMR and 13C NMR spectra were recorded on Bruker 250 MHz with automatic sample changers 
at 25 °C on Chemical shifts (δ) are given in parts per million (ppm) and all coupling constants (J) in 
Hz. Proton chemical shifts were referenced to residual CHD2SOCD3 (δ=2.49, quin) and CHD2OD 
(δ=3.30, quin) signals. 13C NMR chemical shifts were referenced to the solvent (CD3SOCD3: 
δ=39.5, sept; CD3OD: δ=49.0, sept). Analytical HPLCs HPAgilent1100 withauto-sampler,  
LC/MS HP Agilent 1100 with ES and APCI mass detector auto-sampler 
 
Preparation of Nitrophenol Resin (3). In a 50-mL solid-phase extraction (SPE) e cartridge 
containing amino methyl polystyrene resin (1g ,1.01 mmol, 1 eq) pre-swelled in DMF (15 mL) were 
added 4-hydroxy-3-nitrobenzoic acid (2, 3.03 mmol, 555 mg, 3 eq), previously preactiveted with 
DIC (3 eq, 3.03 mmol, 382.39 mg, 469 µL), HOBT (3.30 mmol, 464 mg, 3 eq,) 30 minutes. After 
overnight shaking, the reaction mixture was washed with DMF (20 mL, 5 times), DCM, and 
methanol (20 mL, 5 times alternatively). To remove any undesirable side product, mainly esters, 
DMF (5 mL) and piperidine (0.5 mL) were added to the cartridge and allowed to shake for 1.5 h. 
The resin was filtered and washed with DMF (20 mL, 5 times). The resulting piperidine salt was 
removed via the addition of a 10% HCl solution (in DMF, 20 mL) and was allowed to shake for 1.5 
h. The resin was then filtered; washed with DMF, methanol, and DMC (20 mL, 5 times each); and 
dried by nitrogen gas flow. 
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Solid phase supported dyes 
5(6)-carboxyfluorescein (1.53 mmol, 564.5 mg, 3 eq,), DIC (1.53 mmol, 190.6 mg, 234 µL, 3 eq,) 
(1 eq, 0.505 mmol, 500mg,) in DMF (20ml) were shaked for 30 minutes. The mixture 5(6)-
carboxyfluorescein/HOBt/DIC was then added to nitro phenol aminomethyl polystyrene resin 
(0.505 mmol , 505 mg, 1 eq,). A little amount of DMAP was added before shaking overnight. The 
same procedure was followed to couple to the mixture  5(6)-tetraethylcarboxyrhodamine (1.53 
mmol, 732 mg, 3 eq,), DIC (1.53 mmol, 190.6 mg, 234 µL,3 eq,), in DMF. After overnight shaking, 
the resin was washed with DMF (20 mL, 5 times), DCM, methanol (20 mL, 5 times) and Et2O (20 
ml, 5 times). The resulting resin was then dried in a vacuum oven, overnight at 40°C. 
 
Cleavage of dye from solid support.  
General protocol  
In a 50-mL SPE cartridge 5(6)-carboxyfluorescein or 5(6)- tetraethylcarboxyrodamine polystyrene 
loaded resin (1 eq, 505, mg  0.5 mmol/g), were added 0.9 eq of nucleofilic molecules: 
propargylamine (0.45mmol, 24.8 mg, 31µL), 2,2-dimethoxy ethylamine (0.45mmol, 47.3, 49 µL) in 
3 ml of deareated DMF. On addition of nucleofile the DMF solution turned colour  indicating 
release of the desired labelled product. The reaction mixture was stirred for 30 minutes at room 
temperature. The resin was washed  with the DMF collecting all in a flask , the solvent was 
evaporated under reduced pressure leaving purple oil (molecules labelled with 5(6)- 
tetraethylcarboxyrodamine and orange one  (molecules labelled with 5(6)-carboxyfluorescein). 
Esi-Ms positive mode eluted 95% MEOH 0.1% TFA  
5 ESI-MS m/z: 524.4 (found), 524.6 (expected for [M+H] +); 9 ESI-MS m/z: 414.4 (found), 414.3 
(expected for [M+H] +); 10 ESI-MS m/z: 436.3 (found), 436.4 (expected for [M+H] +); 11 ESI-MS 
m/z: 464.3 (found), 464.4 (expected for [M+H] +); 12 ESI-MS m/z: 574.5 (found), 574.6 (expected 
for [M+H] +) 
 
Thiolated 5(6)-carboxyfluorescein 
5(6)-carboxyfluorescein polystyrene loaded resin (0.2 mmol, 200 mg, 1eq) was treated with N2 
purged DMF (3ml). 2-aminoethanethiol (cysteamine) (0.18 mmol, 15.4 mg, 0.9 eq) in 1ml of 
deareated DMF was added and the mixture maintained under a blanket of nitrogen. On addition of 
Cysteamine the DMF solution turned reddish indicating release of the desired thiolated 5(6)- 
carboxyfluorescein. The reaction mixture was stirred for 30 minutes under N2 before filtering by 
SPE cartridge. The resin was further washed with N2 purged DMF and the solvent evaporated under 
reduced pressure leaving an orange solid which was identified as thiolated 5(6)-carboxyfluorescein. 
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The thiolated compound tends to oxidize to disulfide if in presence of oxygen and must be stored as 
a solid at - 20°C. Thiolated dyes can also be stored in solution if in presence of 0.1 M TCEP 
reducing agent. 
 
Synthesis of 2,2,2-Trifluoro-N-prop-2ynyl-acetamide (13) 
Propargylamine (8.8 4 g, 160 mmol) and TEA (45 ml, 320 mmol, 2eq were dissolved in CH2Cl2 (50 
ml) at 0°C . Trifluoacetic anhydride (25 ml, 180 mmol, 1.13 eq) was added dropwise over 30 min. 
the reaction mixture was warmed to r.t. stirred for 14 h and evaporated in vacuo to a brown oil. 
Et2O (200ml) and 1M NH4OAc (300 mL) were added. The organic layer was separated and washed 
with H2O (100 mL), dried (Na2SO4) and purified by column chromatography eluted with CH2Cl2 to 
yield a yellow oil (17.9 g, 118 mmol, 74 % yield). 
Product 13 (17.9 mg, 118 mmol) were dissolved in 6 ml obtaining a solution of 2.98 g/ml density. 
2,2,2-Trifluoro-N-prop-2ynyl-acetamide 1H NMR (250 MHz, CDCl3) δH 7.19 (1H, br signal, NH), 
4.26 (2H, ddd, J= 5.5, 2.6, 0.4 Hz, CH2), 2.4 (1H, t, J= 2.6 Hz, CH), 13C NMR (62.5 MHz, CDCl3), 
δC 157.2 (q, J=37.9 Hz, COCF3), 115.5 (q, J=287.2 Hz, CF3), 73.4 (CH), 77.4 (C), 30.1 (CH2), ES 
m/z (%) 150.2 (m-H, 100).  
 
5-iodocytosine (14) 
1H NMR (250 MHz, d6-DMSO), δH 7.9 (H, s, C6H), 7.5 (H, br, NH), 6.2 (2H, br signal, NH2) 13C 
NMR (62.5 MHz, DMSO), δC 164.8 (C4), 156.0 ( C=O), 153.2 (C 6), 55.4 (C5, C-I) 
 
TFA-alkynylmethylamino cytosine (15) 
5-iodo-cytosine 14 (300 mg 1.25mmol) were dissolved in DMF (Vol 6.2mL , 0.2M), before 
addition of  2,2,2-Trifluoro-N-prop-2ynyl-acetamide (2 eq, 2.5mmol, 377.55 mg, 126.5 µL), CuI 
20% molar ratio  [0.25 mmol, 47.6 mg], Pd[(C6H5)3P]4 10% in weight [35 mg], Amberlite Ira-67 
(1.25 g, 6.25 mmol, 5mol/eq).The reaction mixture was stirred or 14 h at 40°C and monitored by 
TLC (95:5 DCM/MEOH) comparing the Rf of starting material Rf=0.3 and of Sonogshira product 
Rf=0.5. The reaction mixture was filtered over a plug of SiO2 (5:1 CH2Cl2 : MEOH eluent), the 
solvents were removed at reduced pressure with gentle heating (approx 35 C), giving a crude 
product which was purified by flash chromatography on silica gel (95:5 DCM/MEOH) to afford 
sonogashira product (254mg, 0.97 mmol, 78 % yield). 
1H NMR (250 MHz, d6-DMSO) δH 7.9 (H, s, C6H), 7.5 (H, br, NH), 7.19 (1H, br signal, NH), 6.2 
(2H, br signal, NH2) 4.26 (2H, ddd, J= 5.5, 2.6, 0.4 Hz, CH2), 13C NMR (62.5 MHz, DMSO), δC 
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δC 164.8 (C4), 157.2 (q, J=37.9 Hz, COCF3), 156.0 ( C=O), 153.2 (C 6), 115.5 (q, J=287.2 Hz, 
CF3), 99.5 (C5) 73.4 (CH), 77.4 (C), 30.1 (CH2).  
 
Alkynylmethylamino cytosine (18) 
254 mg 0.97 mmol of product 15, were deprotected with 6 M NH3 in H2O/MeOH. After 2 hours the 
reaction was complete  and ethylacetate (100ml) was added. The organic layer was separated dried 
with Na2SO4, filtrated and evaporated in vacuo. The pure product was obtained 0.87 mmol, 144 mg. 
1H NMR (250 MHz, d6-DMSO) δH 7.9 (H, s, C6H), 7.5 (H, br, NH), 6.2 (2H, br signal, NH2) 4.26 
(2H, ddd, J= 5.5, 2.6, 0.4 Hz, CH2), 2.4 (1H, t, J= 2.6 Hz, CH), 13C NMR (62.5 MHz, DMSO), δC 
164.8 (C4), 156.0 ( C=O), 153.2 (C 6), 99.5 (C5) 73.9 (C alchin), 77.9 (C alchin), 30.1 (CH2).  
 
Tamra-cytosine (20)  
In a SPE cartridge, to nitro phenol amino polystyrene resin (1 eq, 500 mg,  0.5 mmol/g) 
functionalized with 5(6) carboxy rhodamine, were added 0.9 eq (0.45 mmol, 74 mg) of 15 and were 
shaked at room temperature. The nucleoside 20 labelled with 5(6)carboxyrhodamine was furnished 
in 30 minutes pure with an overall yield of 30%. 
 
5-iodo thymine (16) 
1H NMR (250 MHz, d6-DMSO) δH 11.8 (s, 1H, 3-H),  11.3 (s, 1H, N-H), 8.09 (s, 1H, 6-H), 13C 
NMR (62.5 MHz, DMSO), δC 161.8 (C4), 151.5 ( C 2, C=O), 147.3 (C 6), 67.8 (C5).  
 
TFA-alkynylmethylamino thymine (17) 
5-iodo thymine 16 (300 mg 1.26 mmol) were dissolved in DMF (Vol 6.2mL , 0.2M) solution, 
before addition of 2,2,2-Trifluoro-N-prop-2ynyl-acetamide (377.55 mg, 126.5 µL, 2.5mmol, 2 eq) 
CuI 20% molar ratio  [47.6 mg, 0.25 mmol,], Pd[(C6H5)3P]4 10% in weight [35 mg], Amberlite Ira-
67 (1.25 g, 6.25 mmol , 5 mol/ eq) and heated to 40°C. The reaction mixture was stirred or 14 h at 
40°C and monitored by TLC (6:4 Hexane/AcOEt) comparing the Rf of starting material Rf=0.1 and 
of Sonogshira product Rf=0.3.The reaction mixture was filtered over a plug of SiO2 (5:1 CH2Cl2 : 
MEeOH eluent), the solvents were removed at reduced pressure with gentle heating (approx 35 C), 
giving a crude product which was purified by flash chromatography (6:4 Hexane/AcOEt) to afford 
sonogashira product. (247 mg , 0.94 mmol, 75 % yield). 
1H NMR (250 MHz, d6-DMSO) δH 11.8 (s, 1H, 3-H), 11.3 (s, 1H, N-H), 8.09 (s, 1H, 6-H), 7.5 (H, 
br, NH), 4.26 (2H, ddd, J= 5.5, 2.6, 0.4 Hz, CH2),13C NMR (62.5 MHz, DMSO), δC 161.8 (C4), 
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157.2 (q, J=37.9 Hz, COCF3), 151.5 ( C 2, C=O), 147.3 (C 6), 115.5 (q, J=287.2 Hz, CF3), 99.4 
(C5) 73.4 (C alchin), 77.4 (C alchin ), 30.1 (CH2).  
 
Alkynylmethylamino thymine (19)  
247 mg, 0.94 mmol of product 17, were deprotected with 6 M NH3 in H2O/MeOH. After 2 hours 
the reaction was complete  and ethylacetate (100ml) was added. The organic layer was separated, 
dried with  Na2SO4, filtrated and evaporated in vacuo. The pure product (0.84 mmol, 140 mg) was 
obtained. 1H NMR (250 MHz, d6-DMSO) δH 11.8 (s, 1H, 3-H),  11.3 (s, 1H, N-H), 8.09 (s, 1H, 6-
H), 7.5 (H, br, NH), 4.26 (2H, ddd, J= 5.5, 2.6, 0.4 Hz, CH2),13C NMR (62.5 MHz, DMSO), δC 
161.8 (C4), 151.5 ( C 2, C=O), 147.3 (C 6), 99.4 (C5) 73.4 (C alchin), 77.4 (C alchin ), 30.1 (CH2).  
 
Fam-thymine (21) 
In a polystyrene cartridge, to nitro phenol  amino polystyrene resin (1 eq, 500 mg,  0.5 mmol/g) 
functionalized with 5(6) carboxy fluorescein, were added 0.9 eq (0.45 mmol, 74 mg) of  16 and 
were shaked at room temperature. The nucleoside 21 labelled with 5 (6) carboxy fluorescein was 
furnished in 30 minutes pure with an overall yield of 30%. 
1H NMR (250 MHz, (d6-DMSO): 11.8 (s, 1H, 3-H thy), 11.3 (s, 1H, N-H1 thy), 9.26 (1H, t, J=5.3 
Hz, NH, isomer a), 9.15 (1H, t, J=5.3 Hz, NH, isomer b), 8.44 (1H, d, J=0.7 Hz, HC(4) of isomer a), 
8.27 (1H, dd, J1=7.9, J2=1.5 Hz, HC, isomer b), 8.15 (1H, dd, J1=7.9 Hz, J2=1.2 Hz, HC(5) of 
isomer 2), 8.12 (s, 1H, 6-H thy),8.09 (1H, d, J=8.0 Hz, HC(4) of isomer 6), 7.71 (1H, s, HC(7), 
isomer a), 7.39 (1H, d, J=8.0 Hz, HC(7) of isomer 5), 6.73-6.74 (2H, m, CH of isomer 5 and 6), 
6.53-6.64 (4H, m, CH, isomer 5 and 6), 4.11 (2H, dd, J1=5.4 Hz, J2=2.4 Hz, HCCCH2- of isomer 
A), 3.99 (2H, dd, J1=5.2 Hz, J2=2.6 Hz, CH2- of isomer B), 3.17 (1H, t, J=2.4 Hz, HCCCH2- of 
isomer A), 3.10 (1H, t, J=2.4 Hz, HCCCH2 of isomer B). 
 
Part III of my Phd thesis has been difficult to describe because the data have been covered by a 
British Patent Application n. 0718255.3, “Nucleobase Characterisation" of 19th September 2007, 
The University Court of the University of Edinburgh. 
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ABSTRACT 
 
 
Nell’ambito di questo lavoro di tesi la candidata si è occupata dello studio di nuovi sistemi 
molecolari basati su acidi nucleici e analoghi (ODN)  per la realizzazione di sistemi utilizzabili nel 
drug delivery o in diagnostica. 
La prima parte di questo lavoro di tesi ha riguardato la costruzione di sistemi dendrimerici 
utilizzando molecole di ODN ed analoghi, lineari e ramificate, come building blocks 
autoassemblanti, sfruttando la caratteristica che hanno filamenti complementari di acidi nucleici (ed 
analoghi) di legarsi l’uno all’altro in maniera specifica. Sono stati realizzati 2 tipi di sistemi 
dendrimerici: un sistema monomolecolare autoassemblante (A), formato esclusivamente da 
molecole di PNA tridendron e un sistema bimolecolare (B) costituito da un  tridendron di PNA a 
sequenza mista non auto-complementare, e un crosslinker di DNA. Entrambi i sistemi hanno la 
capacità di formare una rete tridimensionale mediante la formazione di ibridazioni specifiche W-C. 
I componenti dei due sistemi sono stati realizzati in fase solida utilizzando una chimica di tipo 
Fmoc per il PNA, e quella del fosforoammidito per il DNA. Tutti gli oligomeri, deprotetti e 
distaccati dal supporto solido, sono stati purificati via  HPLC e caratterizzati da MALDI-TOF e ESI 
-MS. Un dettagliato studio spettroscopico, è stato quindi effettuato su entrambi i sistemi per 
verificare la formazione di una rete oligonucleotidica, consentendo quindi di chiarire le proprietà 
cinetiche e termodinamiche dei sistemi realizzati. Infine, la candidata ha effettuato esperimenti di 
microreologia “Multiple Particle Tracking” (MPT) in collaborazione con il Prof. P. Netti e il dottor 
S. Fusco del Dip. di ingegneria dei materiali dell’Università “Federico II”, per testare la capacità dei 
sistemi in esame  di realizzare idrogels in grado  incapsulare eventualmente farmaci per applicazioni 
in drug delivery. 
Nella seconda parte del lavoro della sua tesi di dottorato, la dott.ssa M. Moccia si è occupata della 
sintesi, caratterizzazione e studi di binding di nuovi analoghi oligonucleotidici, allo scopo di 
esplorare loro nuove possibili applicazioni terapeutiche o diagnostiche. Questo progetto è stato 
realizzato in collaborazione con i dottori G. Roviello e D. Musumeci dell’IBB-CNR di Napoli. 
I nuovi γ-nucleopeptidi ideati (dabPNA) sono basati su un backbone formato da unità di acido 2,4-
diamminobutirrico (DABA) connesse alle nucleobasi attraverso un legame ammidico mediante un 
ponte metilencarbonilico. Dapprima Nielsen, nel 1993, e poi  Meierhenrich, in seguito al 
rinvenimento del diamminoacido DABA e delle nucleobasi nel suolo meteorico,  hanno proposto i 
dabPNA come probabile materiale genetico primordiale. 
Per realizzare gli oligomeri di dabPNA, oggetto del presente studio, sono stati sintetizzati 
innanzitutto i nuovi monomeri tL-dab, tD-dab, aL-dab e aD-dab, a partire da building blocks 
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opportunamente protetti, ottenendo in buona resa i nuovi nucleoamminoacidi chirali 
opportunamente purificati e caratterizzati via NMR ed ESI-MS. 
Inizialmente sono stati sintetizzati gli oligomeri (tL-dab)12 e (tD-dab)6 adottando strategie sintetiche che 
preservino le proprietà ottiche del prodotto, e sono stati effettuati studi di ibridazione con acidi 
nucleici naturali. Dagli esperimenti CD e UV sia con il DNA (dA12) e RNA (A12) non si è rivelata 
nessuna significativa evidenza di legame. Inoltre l’introduzione di un monomero di dabPNA nella 
parte centrale o all’N terminale di un filamento t12 di aegPNA ha portato ad oligomeri caratterizzati 
da una minor affinità di legame verso il DNA complementare rispetto ad un filamento interamente 
costituito da aegPNA, denotando che la presenza di monomeri di dabPNA disturba la struttura della 
duplex PNA/DNA. Siccome entrambi gli enantiomeri del dabPNAs basati su L- o D-DABA non 
legano acidi nucleici naturali abbiamo esplorato la possibilità che nucleopeptidi complementari 
basati su D o L-DABA formare complessi. Questa proprietà è interessante per lo sviluppo di nuovi 
sistemi dendrimerici basati sul DABA, come nuovi materiali, ed anche per la realizzazione di nuovi 
sistemi diagnostici come per esempio molecular beacon. Per verificare questa possibilità i 
monomeri aL-dab e aD-dab sono stati oligomerizzati in fase solida per ottenere gli esameri :(aL-dab)6, (aL-
dab- aD-dab)3 e (tL-dab-tD-dab)3. Dagli esperimenti di CD e UV, abbiamo riscontrato evidenza di legame 
solo nel caso degli oligomeri complementari con chiralità alternata (aL-dab-aD-dab)3 e (tL-dab-tD-dab)3, 
eanche se la stabilità del complesso formato non è molto elevata (Tm= 11°C). Ulteriori esperimenti 
saranno effettuati per stabilire meglio la stabilità e la stechiometria dei complessi nucleopeptidici. 
La terza parte del presente lavoro di tesi di dottorato è stata svolta presso il laboratorio del prof M. 
Bradley presso la School of Chemistry di Edimburgo ed ha riguardato un progetto dal titolo 
“Metodo non enzimatico per analisi SNP (single nucleotide polymorphism)”. I polimorfismi da 
singolo nucleotide (SNP) si riferiscono ad alterazioni di singole basi che si verificano nel genoma 
umano e che danno luogo pertanto a modifiche della struttura e della funzionalità delle proteine, 
relative ai geni modificati . Risulta quindi importante occuparsi delle malattie originate da tali 
polimorfismi. Lo scopo di questo progetto è stato quello di sintetizzare e caratterizzare nuovi 
nucleosidi marcati ciascuno con 4 differenti fluorofori da usare per sviluppare un nuovo metodo di 
rivelazione degli SNP di tipo non enzimatico, utilizzando sia la tecnologia del microarray che quella 
del PNA. In primo luogo è stato messa a punto una nuova metodica di marcatura con fluorofori, 
ottimizzata inizialmente con l’uso di piccole molecole organiche nucleofile, il colorante supportato 
in fase solida viene così facilmente e velocemente rilasciato; successivamente tale metodo è stato 
usato per marcare le basi azotate opportunamente modificate in precedenza. Tale procedura è stata 
utilizzata per ottenere i nucleosidi modificati della citosina e della timina marcati rispettivamente 
con 5(6)-carbossi rodamina e 5(6)-carbossi fluoresceina. Una volta ottenuta tutti e quattro i 
 89 
nucleosidi modificati marcati si potrà procedere alla messa a punto del metodo non enzimatico 
basato sul microarray per la rivelazione degli SNP.  
